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CHAPTER 1 
Introduction 
Epilepsy is a disease defined by the presence of recurrent seizures, where a 
seizure is a period of excessive, synchronous neural activity in the brain.  Symptoms of 
seizures vary depending on the location of the initiating site (seizure focus) and whether 
it spreads across other areas of the brain, but can range anywhere from brief staring 
episodes (‘absence seizures’) to sensing unusual odors to death from sustained, 
generalized convulsions.  As most types of seizures involve a loss of consciousness, even 
mild forms of epilepsy are debilitating for patients since they prevent many common 
daily activities such as driving a car or bathing alone.  Epilepsy is also one of the most 
common neurological disorders occurring in up to 1.0% of the world population (1). 
Approximately two million people in the United States have epilepsy and three percent 
will develop epilepsy at some point in their lives.   
Despite epilepsy’s prevalence, severity, and the fact that it has been recognized 
for millennia (2), very little is known about its underlying cause.  While single gene 
defects in ion channels or neurotransmitter receptors are associated with some forms of 
inherited epilepsy (3-5), these mutations account for only a very small proportion of 
epilepsy cases.  Most cases of epilepsy result from a focal brain region of enhanced 
excitability, which can depolarize rhythmically and cause excitability to spread through 
the brain, leading to generalized convulsions.  Nearly any type of brain lesion can 
produce epilepsy, including trauma, tumor, and cerebrovascular disease, but there is often 
no consistently identifiable pathology (6).  The heterogeneity of causes, combined with 
the fact that most cases have no discernable etiology, have made studying and treating the 
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disease difficult.  Current pharmacological treatments for epilepsy target only the 
symptom of seizures in a general manner, but do not address the underlying brain 
abnormality that generates them (7).  This means that patients must be on medications for 
life, often with severe side-effects due to their lack of specificity for the epileptic areas of 
brain.  In approximately 30% of patients, even these medications cannot adequately 
reduce their seizure frequency (8). 
In recent years, electrical mapping and imaging techniques have allowed for 
surgical resection of epileptic foci in patients with intractable epilepsy which does not 
respond to medications.  Resection is often curative (9), which implies a fundamental 
difference between regions that initiate seizures and nearby areas that do not.  Although 
there are numerous causes of epilepsy, all cases exhibit a similar syndrome of increased, 
coordinated activity, so there may in fact be a final, common, causal pathway.  With this 
in mind, previous studies in our laboratory compared gene expression levels between 
areas of seizure onset and areas not involved in seizures within individual patients 
(10,11).  When these results were compiled across multiple patients with different 
etiologies, a group of approximately 140 genes were found to be commonly differentially 
expressed at seizure onset zones, no matter what originally caused each patient’s 
epilepsy.  Further, many of these genes were localized to cortical layers II and III, and 
synaptic density was increased in these layers as well.  Discovery of these common 
molecular changes will allow animal models of epilepsy to be verified as true molecular 
mimics of the human disease so that targeted therapies developed in them are more likely 
to translate into viable treatments. 
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Interictal spikes in human epilepsy 
In patients with epilepsy, abnormal electrical discharges occur between seizures, 
referred to as “interictal spikes”.  These interictal spikes are small, abnormal discharges 
from focal areas of brain.  Like seizures, they are the product of a population of 
inappropriately-synchronized neurons firing together.  Unlike seizures, they do not spread 
across large areas of the brain and do not cause any recognized symptoms.  However, 
because interictal spikes occur much more often than seizures and develop long before 
actual seizures, there has been a growing interest in the molecular roles of interictal 
spiking in epilepsy (8). The relationship of interictal spikes to seizures is still 
controversial, as they increase in frequency after rather than before seizures (12-15).  
Still, they are most frequent in the areas of brain that initiate seizures in a majority of 
patients, and are used to identify epileptic brain regions for resection surgeries (16-23).  
Some studies have shown that removing areas of high spike activity in the temporal lobe 
is associated with good surgical outcome (19,24,25).  Furthermore, a recent double-blind 
study that used add-on therapy to reduce interictal spiking showed behavioral 
improvements in patients with epilepsy, raising the possibility that interictal spiking itself 
is deleterious to normal brain functioning (26). 
These observations suggest that interictal spikes play an important role in human 
epilepsy, yet reveal the paucity of knowledge about them.  One of the reasons interictal 
spikes have been so poorly studied is the difficulty and subjectivity involved with 
quantifying them.  Spikes are typically marked manually by trained 
electroencephalographers, but thousands of spikes can occur in just a 10-minute 
intracranial electroencephalogram (EEG) sample and there is no strict definition of a 
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spike on intracranial EEG (27-30).  Additionally, spiking patterns within the same patient 
vary greatly over time, so a tremendous amount of EEG would need to be reviewed to 
gain an accurate picture of spiking in each patient (17).  A more objective, automated 
method of spike detection would solve these problems and allow better studies of 
interictal spiking.  Studies based on a reliable detection method might reveal important 
characteristics of interictal spiking that have previously been masked by reviewer 
variability.   
Despite these limitations, previous work in our laboratory supports an important 
role for interictal spikes in epilepsy.  In Rakhade 2007 (31), it was shown that expression 
levels of several genes induced in epileptic regions of brain correlated precisely with the 
frequency and amplitude of interictal spikes measured in the regions of cortex from 
which the samples were taken.  No such correlation was found for any aspects of 
seizures, such as frequency, duration or type.  These results suggest that interictal spikes 
may be able to induce activity-dependent gene expression, and may be necessary for 
either creating or maintaining an epileptic focus.  Experiments to determine whether this 
is actually true would have to be carried out in an animal model, however. 
 
Animal models of epilepsy and interictal spikes 
 Animal models have been used to investigate epilepsy for decades (32), and most 
of them have been reported to generate interictal spikes in addition to seizures.  Rarely, 
however, are interictal spikes the focus of study and their contribution to both pathology 
and epileptogenesis is difficult to disentangle from that of seizures.  An ideal model for 
the study of clinically-important interictal spikes in animals would be to mimic the 
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human phenomenon as closely as possible.  This would require interictal spikes in the 
absence of frank seizures that are similar to those observed in humans, are chronic, 
spontaneous, and are not associated with significant neuronal toxicity or death.   
 Both acute and chronic interictal spikes have been observed in animal models. In 
hippocampal slice culture, gamma-aminobutyric-acid-A (GABAA) blockade (33-35), low 
extracellular magnesium concentration (36), low extracellular calcium (37,38), kainic 
acid (39,40), and 4-aminopyridine (41) have all been used to generate interictal-like 
activities (42).  The advantage of these methods is that interictal activity without ictal 
discharges can be generated in order to study the electrophysiological properties of 
interictal spikes independently from seizures.  Disadvantages are that the relationship of 
in vitro discharges to those generated in intact animals is unclear and nothing can be said 
about ‘higher order’ phenomena such as behavior with in vitro models.  Acute in vivo 
models are better suited to address these problems.  Systemic administration of GABA-
blocking substances, kainic acid, or pilocarpine produces interictal spikes, but these can 
also be injected focally.  After penicillin injection into the cortex, focal interictal spikes 
as well as seizures occur and can last for six to eight hours (43-45).  Kainic acid or 
pilocarpine given systemically produce acute status epilepticus that can last for several 
hours, after which interictal spikes are observed (46-51).  Pentylenetetrazol is generally 
used as a convulsant agent, but in the right dose can produce spikes with no detected 
seizures and produces minimal tissue damage (52).   One question that remains with all of 
these acute models of epileptiform activity is whether they are truly identical to the 
spontaneous interictal spikes generated chronically in patients with epilepsy. 
 Chronic models of epilepsy are generally produced by an initial lesion, followed 
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by a latent period, and the subsequent development of spontaneous epileptiform activities 
(42).   Most models focus on the hippocampus, and commonly used methods of modeling 
human hippocampal epilepsy are electrical kindling, or systemic administration of 
pilocarpine or kainic acid.  Kindling involves repeated electrical stimulations which cause 
seizures.  If done enough times, kindling can lead to the production of spontaneous 
interictal spikes and seizures (12,53,54).  Status epilepticus induced by either pilocarpine 
or kainic acid causes significant neuronal damage in the hippocampus, but after a latent 
period, large interictal spikes mixed with spontaneous seizures occur chronically in a 
subset of animals (46-51).  For chronic neocortical epilepsy, the most common 
techniques are application of either toxic metals or tetanus toxin.  When metals, such as 
cobalt, are directly applied to the cortex, spontaneous interictal and ictal activities are 
observed and can persist for one or more weeks, depending on the method of application 
(12,53,54).  Limitations of using metals are that the epileptiform activity requires 
continued presence of the irritant and extensive tissue destruction is seen at the site.  This 
is likely different than lesions that produce epileptic foci in humans, such as brain injury, 
which are usually single, initial insults (1,55,56).   
 Tetanus toxin injected directly into either the neocortex or hippocampus produces 
a variety of transient excitatory patterns dependent on the injection site (57-60).  It is a 
good model of chronic epilepsy because it does not produce significant neuronal toxicity 
as many of the other focal models do and does not produce the tissue destruction 
observed after prolonged status epilepticus.  Tetanus toxin preferentially binds to the 
gangliosides of inhibitory neurons, where it is taken up by receptor-mediated endocytosis 
and cleaves synaptobrevin (VAMP-2), which prevents the release of vesicles containing 
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inhibitory neurotransmitters (61-63).  An initial injection of tetanus toxin is followed by a 
latent period, after which interictal spikes and spontaneous seizures can persist almost 
indefinitely (>7 months) (60,64,65).  Most intriguingly, Brener et. al. noted that, unlike 
injections into hippocampus or motor cortex that produce seizures early on, injection of 
small amounts of tetanus toxin into the somatosensory cortex results predominantly in 
interictal spikes with only infrequent seizures (60).  This model seems to offer the ideal 
characteristics to study interictal spikes in animals since it is a chronic, spontaneous in 
vivo model, without seizures early on and minimal neuronal cell loss.   
 
Psychiatric and behavioral comorbidities of the interictal state 
 While interictal spikes do not have any widely-accepted symptoms, epilepsy is 
associated with a broad range of comorbid conditions.  Patients with epilepsy are more 
likely to have attention deficit hyperactivity disorder (ADHD) (66-72), depression 
(68,73-78), anxiety disorders (68,73,75,77-79), and other psychiatric conditions 
(68,71,78-82).  Since these patients are usually in the interictal state between seizures, it 
is possible that interictal spikes may contribute to these pathologies.  Interictal spikes in 
the absence of seizures are not widely thought to have definite symptoms, but they have 
not been thoroughly studied and there is some preliminary evidence that they may 
actually have subtle effects.  Interictal spikes are best studied on intracranial EEG, as 
only the largest 1% of spikes are even detectable on scalp EEG (83), but it is clearly 
unethical to place intracranial grids on anyone not being considered for epilepsy surgery.  
As such, it is very difficult to study interictal spikes in humans outside of their role in 
epilepsy.  Nevertheless, EEG abnormalities have been noted in a wide range of 
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psychiatric disorders for decades.  In many of these studies, however, all EEG 
abnormalities were lumped into a single ‘abnormal EEG’ description and were not 
categorized specifically as interictal spikes. Several studies describe a high incidence of 
EEG abnormalities in anxiety disorders, panic disorders, and obsessive-compulsive 
disorder (84,85).  However, one large community study by Bridgers found that 
epileptiform discharges, specifically, were correlated with symptoms of anorexia nervosa, 
depression, mania, personality disorders, suicidality without depression, nonpsychotic 
explosive behavior, and the effects of psychotropic medications (86).  Individuals 
displaying antisocial and aggressive tendencies have also been found to display a wide 
range of EEG abnormalities, including epileptiform discharges (87-91).  Given the wide 
array of psychiatric symptoms and the comorbidity of psychiatric diseases with epilepsy, 
long term human recordings and focused behavioral studies in animals will be needed to 
establish any causality between these abnormal brain activities and behaviors. 
 More direct associations of interictal spikes with specific cognitive behaviors 
have also been noted on scalp EEG.  A recent double-blind study that reduced interictal 
spiking using lamotrigine  as an add-on seizure therapies showed significant behavioral 
improvements in patients with epilepsy raising the possibility that interictal spiking is  
deleterious to normal brain functioning (26).  Some studies suggest an association 
between high frequency interictal spikes and cognitive and behavioral decline in children 
with autism (92,93).  Inui, et. al. found that spike variants were significantly higher 
among patients with mood-incongruent psychotic mood disorder (33%), schizoaffective 
disorder (33%), and schizophreniform disorder (30%) as compared with patients with 
nonpsychotic mood disorder (3.2%) and schizophrenia (0%) (94).  Interictal spikes have 
9 
 
even been associated with self-injurious behavior among tuberous sclerosis patients (95).  
With a potential role in such a wide range of disorders, it would be advantageous to 
develop a better understanding of interictal spikes through animal models. 
 
Genomic perspective on epilepsy 
 While this project will focus largely on specific protein-coding genes and 
pathways in epilepsy, modern techniques now allow for broader analyses to be done, 
such as investigating epigenetic modifications, genomic instability and genome-wide 
association studies.  Many genetic association studies have been conducted in epilepsy, 
but most have been underpowered and have not yielded consistent susceptibility genes. 
[for review see (96)].  Recently though, results of the first large-scale, genome-wide 
association study in epilepsy were released (97).  This study compared 3445 patients with 
partial (focal) epilepsies to 6935 controls in order to identify common patterns of genetic 
susceptibility.  Even with a study this large, however, the authors found no significant 
genome-wide association and were forced to conclude that common genetic variation 
plays only a minor role in predisposition to partial epilepsies.  They instead propose that 
epilepsy be considered under the “common disease-rare variant” hypothesis (98), where 
many rare genetic variants underlie a common disease.  Limitations of this study are that 
it was carried out in an entirely European population and that types of epilepsy were 
ignored.  It is therefore possible that a similar study in a different population or which 
focuses on a specific type of partial epilepsy may have more success in identifying 
common susceptibility variants.  Still, these initial results argue against a productive role 
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for these types of association studies in epilepsy and leave acquired, focal models of 
epilepsy as the best choice for modeling what is known of the human disease. 
 Epigenetic modifications have been implicated in Alzheimer’s disease (99-102), 
Huntington’s disease (103-106),  and many other neurological disorders [for review see 
(107)], so epigenetics may play a role in epilepsy as well.  The first evidence of 
epigenetic involvement in epilepsy came from one of the older anti-seizure medications 
still in use today, valproic acid.  In addition to enhancing GABAergic function, valproic 
acid can also inhibit histone deacetylases (HDACs) at therapeutic concentrations (108).  
Kainic acid, one of the most commonly used compounds for modeling epilepsy in 
vivo,induces a rapid phosphorylation of histone H3 in dentate gyrus neurons and a more 
widespread and sustained acetylation of histone H4 in hippocampal neurons (109,110).  
Three hours after the induction of a seizure, histones H4 on the BDNF promoter show 
hyperacetylation which correlates with increased mRNA levels.  The promoter of the 
metabotropic glutamate receptor (GluR2) also shows epigenetic regulation, with histones 
H3 and H4 rapidly deacetylated after seizures and corresponding to mRNA 
downregulation (111).  In the electroconvulsant model of epilepsy, these findings from 
the kainic acid model were not only recapitulated, but also showed changes in histones 
H3 and H4 on the CREB promoter (112).  Given that the few studies investigating 
epigenetic modifications in epilepsy thus far have already shown positive results and that 
two genes with known alterations in epilepsy, BDNF and CREB, have been implicated, 
epigenetics is likely to play an important role in epilepsy and merits further study. 
 Recent studies have shown that genomic instability, such as copy number variants 
(CNVs), are associated with neurological disorders like ADHD (113,114) and autism 
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(115), so it is reasonable to conclude that genomic instability may be involved in epilepsy 
as well.  One large study using Illunima genome-wide genotyping arrays followed by 
comparative genomic hybridization (CGH) found deletions at 16p13.11 in 23 of 3812 
epilepsy patients, while none of the 1299 controls showed deletions larger than 16kb 
(116).  Another study identified a microdeletion at 15q13.3 in 12 of 1,223 (1%) of 
idiopathic, generalized epilepsy cases using array comparative genomic hybridization 
(aCGH) (117) while a different study found this same deletion in 7 of 539 (1.3%) cases 
and then showed that it seems to behave as a susceptibility variant (118); it is found in 
some but not all family members with epilepsy and some unaffected members also carry 
the deletion.  The same group then extended their search to additional large, recurrent 
microdeletions which were known to occur more frequently in schizophrenia, psychotic 
disorder, autism and mental retardation (119).  This study used single nucleotide 
polymorphism (SNP) arrays, followed by validation with quantitative polymerase chain 
reaction (qPCR) and aCGH, and yielded positive results for the microdeletions at 15q11.2 
(12/1234 cases versus 6/3022 controls) and 16p13.11 (6/1234 cases versus 2/3022 
controls). Finally, seizures induced in the kainic acid animal model of epilepsy show 
instability of the mitochondrial genome (120).  In this model, acute status epilepticus 
increased oxidative mtDNA damage, which coincided with mitochondrial H2O2 
production and a transient decrease in mtDNA repair capacity.  In the chronic phase of 
this model, up to three months after status epilepticus, mitochondria showed increased 
reactive oxygen species production, accumulation of mtDNA damage and impaired 
mtDNA repair capacity.  Overall, genomic instability does not appear to be involved in 
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most cases of epilepsy, but few studies in this area have been done and more prevalent 
stability changes may be found in the future. 
 
Project overview 
 In this project, we first show the high variability between professional reviewers 
in marking interictal spikes on intracranial EEG, and then develop and test an automated 
detection method to solve this problem.  Next, we use this automated detection algorithm 
to identify spikes on intracranial EEG in both tumor and non-tumor patients in order to 
determine the best spiking parameters to identify the seizure onset zone in each group.  
We then develop and characterize an animal model of chronic, neocortical interictal 
spiking to test our observations previously made in human epilepsy and to have a 
molecularly-accurate model on which to test new therapeutics.  Finally, we show that 
interictal spikes are associated with behavioral changes in this animal model and that a 
targeted inhibitor can both prevent the development of a spiking focus and normalize 
behavior. 
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CHAPTER 2 
High inter-reviewer variability of spike detection on intracranial EEG addressed by 
an automated multi-channel algorithm 
INTRODUCTION 
 Interictal spikes are abnormal discharges that occur between seizures in patients 
with epilepsy.  They are frequently generated in the same regions of the brain that initiate 
seizures (16,17), but their exact role in epileptogenesis and the induction or protection 
from seizures remains controversial and requires further study.  A significant barrier to 
such studies comes from the laborious nature of quantifying the thousands of interictal 
spikes that can occur in a single recording, and the fact that spiking rates vary greatly 
over time (17) within patients, meaning that many samples have to be marked per patient 
to get an accurate picture of the spiking pattern.  There is also tremendous variability 
between EEG reviewers on exactly what constitutes a spike on subdural 
electrocorticography (ECoG) (29,121).  
 To address these issues, we first conducted a study of inter-reviewer variability in 
marking interictal spikes in ECoG and, second, compared these results to an automated 
spike detection algorithm.  While many algorithms have been developed for the detection 
of interictal spikes, most are designed for scalp recordings (122), and those few that were 
developed specifically for ECoG were either run on single channels or had humans 
validate spikes after they were already detected by an algorithm (29,121,123,124).  Here, 
we validated a novel automatic spike detection algorithm that emulated human reviewing 
methods by analyzing multi-channel ECoG sections obtained from 10 patients.  We 
compared its performance to three independent human reviewers. 
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METHODS 
 Intracranial EEG recordings for this study were obtained from 10 patients 
undergoing two-stage surgical resections at the Comprehensive Epilepsy Program at 
Wayne State University (#0860000MP2F, Wayne State University Human Investigation 
Committee). These patients represent an equal mix of children (8 months-14 years) and 
adults (20-54 years), and were selected to include a wide range of activity levels and 
spike morphologies.  Recordings were obtained with a Stellate Harmonie digital recorder 
(Stellate Inc., Montreal, PQ, Canada) sampled at 200Hz, and 10-minute sections were 
selected from periods of quiet wakefulness separated by at least six hours from a seizure.  
The average number of channels recorded per patient was 95.9 (SD ± 16.5; range 65-
128). Three trained encephalographers independently reviewed these sections in the same 
referential montage (each recording electrode compaired to a single, designated 
‘reference’ electrode outside the brain surface).  Detections which occurred on the same 
channel within 115ms of another reviewer’s mark were taken as detections of the same 
spike.  This distance was chosen to cover the variation in manual marking of spikes 
without picking up marks that may occur on adjacent spikes.  The use of distances 10ms 
above and below this value produced identical results.  As there is no true ‘gold standard’ 
for comparison, each reviewer was compared to the set of all detections by the other two 
reviewers to calculate sensitivity (true positives/(true positives+false negatives)) and 
precision (true positives/(true positives+false positives)) for each patient.  Finally, we 
used each reviewer’s spike detections to generate a ranking of channels from highest 
spike frequency to lowest.  We then compared these rankings between reviewers in each 
patient by calculating Kendall’s coefficient of concordance (W).  Spearman’s rank 
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correlation coefficient was also calculated for each reviewer pair, as this is a more 
common measure of non-parametric correlation and so human reviewer performance 
could be compared to algorithm performance. 
 The spike detection method was developed as a Matlab program which interacts 
directly with the Stellate ECoG files (Algorithm overview in Figure 1A).  It extracts 
successive one-minute blocks of data from the ECoG recording, with each block 
containing the data for all the recorded channels during that minute.  First, channels 
whose average slopes are more than 10 standard deviations outside the mean for all 
channels are eliminated as artifactual, after which the data are bandpass filtered between 
20 and 50Hz in order to identify interictal spikes (Figure 1B, Similar to Brown, et al. 
2007).  Peaks with amplitudes outside four standard deviations of the channel mean are 
noted as potential spike locations for further consideration.  The original data are then 
filtered at 1-35Hz and all channels are scaled by a single scaling factor as an entire block.  
This method of scaling all channels as one block was chosen because it most closely 
approximates how a human reviewer adjusts sensitivity to review a recording and 
because scaling individual channels tends to cause over-marking of less active channels 
and under-marking of very active channels (Figure 1C).  Once the data have been scaled, 
the amplitude and slope of each halfwave of the potential spikes identified previously are 
calculated and the values are compared to static thresholds.  Waveforms that exceed 
amplitude and slope thresholds are marked as interictal spikes.  All development and 
testing of the algorithm was done on a separate set of ECoG samples from the testing set 
used in this study (31). 
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 Algorithm performance was evaluated both by the ability to correctly identify 
individual spikes marked by human reviewers and the ability to correctly rank channels 
by spike frequency.  We did the same comparison using the commercial spike detector 
included with Stellate’s Harmonie software.  Optimal thresholds for each were 
determined prior to their use in this study on a different group of patients.  Sensitivity and 
precision were calculated separately for spikes marked by at least one reviewer, at least 
two reviewers, and all three reviewers.  To evaluate the performance of the two automatic 
algorithms (ours and Stellate’s) in ranking channels by spike frequency, Spearman’s rank 
correlation coefficient was calculated between the channel ranking of each method and 
the average channel rank from the three human reviewers.  
 Finally, to determine whether spikes detected by the algorithm but no human 
reviewers were truly false positives, ten randomly-selected ‘incorrect’ marks per patient 
were later shown to each of the three reviewers who were asked to decide whether these 
detected spikes were real or not. 
 
RESULTS 
A total of 78,743 spike detections were made by human reviewers from the 10 
different patients.  Surprisingly, only 23.7% of these were marked by at least two 
reviewers and just 3.1% by all three reviewers (Table 1).  Overall, human reviewers 
performed poorly in regard to identifying each other’s spikes (Table 2A.  Sensitivity: 
27.7±12.5%; precision: 50.7±18.5%), but showed good agreement in many (but not all) 
patients when simply ranking channel activity from highest to lowest spiking (Table 2B.  
Kendall’s W: 0.752±0.12).  Spearman's rank correlation coefficient, a similar measure of 
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ranking agreement for pairs of data, gave an average value of 0.660±0.02 when 
calculated for all reviewer pairs across the 10 patients.  
To improve quantitative interictal analyses, we developed an automatic spike 
detection algorithm that uses a combination of frequency filtering and examination of 
entire blocks of channels (Figure 1).  We compared the performance and channel 
rankings to the three human reviewers as well as a commercial spike detection program 
included with our EEG software.  Consistent with and somewhat better than we found 
between reviewers, the algorithm gives an overall average correlation coefficient of 
0.750±0.16 for channel ranking, while the commercial detector's was 0.574±0.27 (Table 
2B).  While the algorithm detected more spikes than any single reviewer (50,315 vs. 
39,802 for highest reviewer), it performed with similar sensitivity and precision for each 
of the three human reviewers (Table 2C), and yielded better results than the commercial 
detector (Table 2D).   
 To determine whether spikes picked up by the algorithm, but none of the human 
reviewers were genuinely false positives or simply missed by the reviewers, 10 
randomly-selected spike detections for each of the 10 patients were presented in the 
context of the entire recording to each of the three reviewers.  They were then asked to 
decide whether these detected spikes were real or not.  The number of spikes originally 
detected only by the algorithm, but then later validated by human reviewers varied widely 
among the three reviewers (Table 3, Mean: 31.3±30.4%; Reviewer 1: 65%; Reviewer 2: 
6%; Reviewer 3:  23%)  This indicates that many of the ‘false positives’ generated by the 
algorithm may actually be 'real' spikes.   
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DISCUSSION 
 This is perhaps the largest study of inter-reviewer variability in the identification 
of interictal spikes in intracranial EEG.  There was surprisingly poor agreement 
(3.1±2.7%; range 0-7.4% for different patients; Table 1) between three human reviewers 
in the identification of specific interictal spikes, despite all being professional 
encephalographers and two of them (R1 and R3) training at the same institution.  These 
results are in line with previous studies which compared reader variability using shorter 
files or individual channels (28,121,124-126).  While there was significant disagreement 
on the identification of individual spikes for a given patient, the reviewers generally 
agreed on the ranking of channels by spike frequency.  This is important because 
determination of the highest-spiking channels is often the main clinical use for 
quantifying interictal EEG.  These findings also underscore the need for automated 
methods of spike detection which function reliably across a wide range of ECoG types 
(28-30,121).   
 Our detection algorithm was able to identify spikes with similar sensitivity and 
precision as the human reviewers, and did an excellent job of ranking channels based on 
interictal spiking activity (Figure 1D, Table 2B).  Key advantages to this algorithm are 
that it requires no human intervention or tweaking of parameters, is fast enough to be run 
‘on-line’ as the ECoG is being recorded, and its performance was validated in a 
completely ‘real world’ environment.  Previous detection algorithms have been tested 
only against a small set of pre-extracted spikes or single channels from each patient, 
while here we show that our algorithm performs well when reviewing entire segments in 
a way that mimics how a human reviewer would see the ECoG.  A reliable spike 
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detection algorithm with good agreement between different reviewers could improve both 
patient care and research on interictal spiking.  
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CHAPTER 3 
Morphological parameters of interictal spikes to identify seizure onset zones in 
lesional and non-lesional patients 
INTRODUCTION 
 Interictal spikes are often used to assist in the identification of seizure onset zones 
for epilepsy resection surgeries.  Frequency of spiking is often the main aspect examined, 
and while this method has positive results (19,24,25), it is far from perfect.  Depending 
on the study, the electrode of maximum spike frequency is located in the seizure onset 
zone in anywhere from 50-100% of patients examined (16,17,22).  In this chapter, we 
attempt to improve the ability of quantitative interictal electrocorticography (ECoG) to 
identify seizure onset zones by examining how several additional morphological 
parameters of interictal spikes relate to seizure onset areas. 
 Next, we examine the use of electrocorticography and interictal spike detection in 
patients with epilepsy caused by brain tumors.  Brain tumors are a common cause of 
epilepsy in adults, with more than one-third of all adults with brain tumors developing 
epilepsy, and more than 50% in cases that involve the cerebral hemispheres (127,128).  
Rarely, however, is a two-stage surgery with placement of electrocorticographic grids 
done in these patients to identify seizure onset areas.  This is partially due to the 
additional stress and invasiveness that would be inflicted on patients who may not have a 
good prognosis even after surgery and partially due to an assumption that removal of the 
tumor should allow the epilepsy to be cured.  If this assumption is not correct though, the 
use of intracranial electrocorticography to identify areas of seizure onset outside of the 
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tumor may improve outcome in these patients.  Further, it may be possible to identify 
parameters of interictal spiking which could help detect tumor margins for resection. 
 
METHODS 
 
Patient clinical and electrocorticographical data 
Intracranial EEG recordings for this study were obtained from 16 non-lesional 
patients and 11 lesional patients undergoing two-stage surgical resections at the 
Comprehensive Epilepsy Program at Wayne State University (#0860000MP2F, Wayne 
State University Human Investigation Committee).  Lesional patients ranged in age from 
22-54 years (Mean 40.7±8.5), and included a variety of tumor types (Table 4), while non-
lesional patients ranged in age from 17-56 years (Mean 36.7±11.3).  The placement of 
intracranial grids on lesional patients was a clinical decision and was not influenced by 
this study.  Recordings were obtained with a 128-channel Stellate Harmonie Digital 
recorder (Stellate Inc., Montreal, PQ, Canada) sampled at 200Hz.  Recording electrodes 
were given one of three “Seizure Categories” by a clinical encephalographer:  Seizure 
Onset, Seizure Spread, or Control.  Seizure Onset zones were identified by sustained 
rhythmic changes on EEG that were clearly distinct from background rhythms and 
associated with the patient’s seizure type, while Seizure Spread electrodes are those that 
pick up these rhythmic discharges within seven seconds of seizure onset.  Control 
electrodes are not involved in seizures.   
For interictal analysis, three 10-minute sections of ECoG were selected for each 
patient from periods of quiet wakefulness separated by at least six hours from a seizure.  
22 
 
Interictal spikes were then detected using the automated method validated previously in 
Chapter 2.  The detected spikes were broken into halfwaves by a Matlab (MathWorks, 
R2008b, Natick, MA) script as described previously (31) so that amplitude, slope and 
duration could be measured for each halfwave of each spike (Amplitude 1, Duration 1, 
Slope 1, Amplitude 2, Duration 2, Slope 2), as well as spike power (frequency * 
(Amplitude 1 + Amplitude 2)).  The average value of each of these parameters was then 
calculated for each channel in a recording and then averaged across the three recordings 
per patient.   
 
Three dimensional brain reconstructions and tumor distance calculation 
 Three dimensional reconstructions of each patient’s brain, including the location 
of recording electrodes and tumors if present, were generated from magnetic resonance 
imaging (MRI) and computed tomography (CT) scans.  These scans were done as part of 
normal pre-surgical evaluation and treatment.  First, a pre-operative T1-weighted MRI 
sequence was imported using BrainSuite09 (David W. Shattuck, Laboratory of 
Neuroimaging, UCLA, http://www.loni.ucla.edu/Software/BrainSuite), and the included 
tools were used to strip away the skull and leave only the underlying brain.  After 
creating and exporting a three-dimensional surface rendering of the patient’s brain, this 
surface was subsequently imported into the custom software program, Smap (Dr. Jing 
Hua and Darshan Pai, Graphics and Imaging Laboratory, Wayne State University 
Computer Science Department).  Using this software, a post-implantation CT showing 
the patient’s electrode grid locations was aligned and coregistered to the pre-operative 
MRI.  An intensity threshold for the CT was then manually chosen so that only the metal 
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electrodes were visible.  The software was then able to overlay the CT onto the MRI of 
the patient’s brain and extrapolate electrode positions.  All electrodes were then manually 
verified using intraoperative photographs to ensure correct placement. 
 In lesional patients, tumor locations were manually outlined on each slice of a 
pre-operative MRI by a neurologist, and these markings were then turned into three-
dimensional renderings by the Smap software.  Finally, with the reconstruction of the 
patient’s brain, the electrode locations, and the tumor location, linear distance to tumor 
was calculated for each electrode in each patient using the Smap software. 
 
Correlation of spiking parameters to seizure category and tumor distance 
 To investigate which interictal spiking parameters best correspond with seizure 
category, morphological parameters of interictal spikes were first normalized to Z-scores 
(forcing the data to have a mean of 0 and standard deviation of 1) within each patient so 
that the data from multiple patients could be combined.  Taking seizure category as an 
ordinal variable where Seizure Onset is more ‘epileptic’ than Seizure Spread, which is in 
turn more epileptic than Control, we then calculated Spearman’s rank correlation 
coefficient for each spiking parameter.  The non-normal distribution of the measured 
spiking parameters also required us to use the non-parametric Spearman’s correlation for 
calculating correlations with tumor distance as well.  Correlations with p values greater 
than 0.01 after Bonferroni correction for multiple comparisons were discarded. 
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Unordered relation of spiking parameters to seizure category and tumor distance 
 Based on the results of the above study and because the assumption that seizure 
category can be treated as an ordinal variable may not be correct, we also examined 
whether any of the three seizure category groups differed from each other in terms of 
morphological spiking parameters.  Due to the non-normal distribution of data, the 
Kruskal-Wallis test was used to look for differences between the seizure category groups.  
If this test was significant, it was then followed with a Mann-Whitney U-test to determine 
which pairs within the three categories significantly differed from each other.   
 
RESULTS 
 
Correlation of spiking parameters to seizure category 
 In non-lesional patients, seizure category was significantly correlated (p<0.01 
after Bonferroni correction) with five parameters of interictal spiking: frequency, 
amplitude of the first halfwave, slope of the first halfwave, amplitude of the second 
halfwave and spike power (Table 5).  All these correlation coefficients were positive, 
indicating that more ‘epileptic’ areas of brain have more frequent, larger and steeper 
spikes than more normal areas.  In lesional patients, seizure category was positively 
correlated with frequency, duration of the second halfwave and spike power.  It was 
inversely correlated with tumor distance, meaning that brain areas closer to tumors are 
more likely to generate seizures. 
 
Correlation of spiking parameters to tumor distance 
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 Electrode distance from tumor was significantly positively correlated with spike 
frequency, duration of the first halfwave, and spike power.  It was inversely correlated 
with amplitude of both halfwaves and the slope of both halfwaves.  Together, these 
results would mean that brain areas closer to tumors spike less frequently than farther 
areas, but have larger and steeper interictal spikes.   
 
Unordered relation of spiking parameters to seizure category and tumor distance 
 While the above correlations are statistically significant, the actual correlation 
coefficients are extremely small, which casts doubt on their biological relevance.  One 
issue may be the assumption that the three electrode seizure categories ‘seizure onset’, 
‘seizure spread’ and ‘control’ can be treated as ordered.  Therefore, we analyzed the same 
dataset again, this time treating seizure category as a nominal variable.  Significant 
results from the Kruskal-Wallis test (non-parametric equivalent of one-way ANOVA) 
were followed up with pairwise Mann-Whitney U tests, holding overall α to less than 
0.05.  Under these conditions, control electrodes in non-lesional patients showed less 
frequent spiking, smaller amplitude of both halfwaves, smaller slope of the first halfwave 
and less total spike power.  In all cases, control electrodes were significantly different 
from both seizure onset and seizure spread electrodes, while no difference was seen when 
comparing seizure onset to seizure spread electrodes.  The similarity of seizure onset to 
seizure spread electrodes likely explains the poor values for correlation coefficients seen 
previously.   
 In lesional patients, control electrodes demonstrated a lower spike frequency, 
shorter duration of the second halfwave, less total spike power and a greater distance 
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from the patient’s tumor.  Once again, control electrodes significantly differed from both 
seizure onset and seizure spread electrodes, while seizure onset and seizure spread 
electrodes never differed from each other.   
 
Best parameters to identify seizure onset zones 
 A commonly reported measure of the ability of interictal spike frequency to 
identify the seizure onset zone is the percentage of patients in which the highest spiking 
electrode is contained within the seizure onset area.  We therefore conducted this survey 
with all the individual parameters in our dataset to see which was most reliably maximal 
in seizure onset areas (Table 6).  The typical measure of spike activity, frequency, was 
maximal in seizure onset electrodes in 4/16 patients, and was never at a minimum in 
seizure onset electrodes.  Slope of the first halfwave and spike power also identified 
seizure onset electrodes in as many patients as spike frequency, while the other 
parameters did not perform as well (Figure 2).  These three parameters were also 
significantly correlated to seizure category and significantly distinguished control 
electrodes from those involved in seizures by the Kruskal-Wallis test, suggesting they 
may all be equally good measures of identifying seizure onset zones in non-lesional 
patients. 
 In contrast to non-lesional patients, spike frequency was only maximal in seizure 
onset electrodes in 2/11 lesional patients.  In this group, duration of the second halfwave 
was maximal in seizure onset electrodes in 4/11 patients and was also significant by the 
Kruskal-Wallis test.  Adding in the fact that it also had a higher Spearman’s rank 
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correlation coefficient to seizure category, duration of the second halfwave is a superior 
marker of seizure onset zones to spike frequency in lesional patients (Figure 3).   
 
Seizure onset zones lie outside the tumor area in the majority of patients 
 While areas near tumors are more likely to be seizure-generating than distant 
areas, many patients have additional seizure foci outside the immediate area of the tumor 
as well.  In 7/11 patients in this study, seizure onset electrodes were located greater than 
two centimeters away from the nearest tumor margin, sometimes on entirely different 
lobes of the brain (Figure 3).  The type of tumor may influence the chance that a seizure 
onset zone will occur outside of the immediate tumor area as well, since 4/4 patients with 
‘high grade’ tumors (WHO Grade >=3) had distant seizure onset zones, compared to only 
3/7 patients with ‘low grade’ tumors (WHO Grade <=2).  The small sample number does 
not give this study enough power to determine whether a true difference exists though 
(p=0.214, two-tailed t-test for difference in proportions).  Overall, the average distance to 
the farthest seizure onset electrode across all lesional patients was 3.45cm (SD±1.76; 
range 1.29-6.86), suggesting that a simple “lesion-ectomy” is unlikely to remove the 
entire seizure onset zone in many patients. 
 
DISCUSSION 
 
Seizure onset and spread zones differ from non-epileptic brain 
 This study showed rather poor correlation between spike parameters and electrode 
seizure category.  While statistically significant, the Spearman rank correlation 
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coefficients between spiking parameters and seizure category were very low and may not 
be biologically relevant.  However, this is likely due to seizure category being treated as 
an ordinal variable, expecting seizure onset electrodes to be more epileptic than seizure 
spread electrodes.  Comparing spike parameters between each seizure category showed 
that control electrodes consistently differed from seizure onset and seizure spread 
electrodes, but onset electrodes did not differ from spread electrodes.  In the parameters 
examined here then, onset electrodes were not distinguishable from spread electrodes. 
 
Spiking parameters that identify seizure onset zones differ in lesional and non-
lesional patients 
 Putting together the results from the correlations, the Kruskal-Wallis tests, and the 
number of patients where highest parameter value was located in a seizure onset 
electrode brings out different measures of spiking as best for identifying seizure onset in 
lesional and non-lesional patients.  In non-lesional patients, frequency, slope of the first 
halfwave and spike power all performed similarly and were maximal at seizure onset 
electrodes in 25% of the non-lesional patients examined.  Although this is poorer than the 
rates reported in other recent studies which range from 50-100% (16,17,22), examining a 
single electrode per patient is not a terribly robust measure.  Interestingly, results from 
Spearman correlation and Kruskal-Wallis tests in lesional patients only overlap in spike 
frequency and power with non-lesional patients.  In lesional patients, duration of the 
second halfwave stands out as the best measure for identifying seizure onset areas, with 
twice as many patients showing maximal duration in a seizure onset electrode as with 
spike frequency.  Additionally, the correlation coefficient for duration is nearly twice that 
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of spike frequency, again suggesting that this is a better measure in lesional patients than 
spike frequency.  Quantitative interictal electrocorticography has not previously been 
examined in tumor patients, so the results of this study are important because they show 
that past research in non-lesional patients cannot necessarily be applied to lesional 
patients. 
 
Proximity to tumor is not the best predictor of seizure zones 
Perhaps the most interesting result of this study is that areas of seizure onset in 
tumor patients are often not directly adjacent to tumors.  In most patients (n=7/11), 
seizure onset zones exist far from the actual tumor, and this may be more likely in more 
aggressive tumors.  In fact, duration of the second halfwave was a better predictor of 
seizure onset zone than distance from the tumor.  The areas immediately surrounding 
tumors seem to have low interictal activity as well, with higher spike frequency 
correlating well with distance from tumor.  These results could help guide the critical 
clinical decisions involved in deciding which areas of the brain to resect in tumor patients 
with comorbid epilepsy. 
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CHAPTER 4 
Characterization and pharmacologic inhibition of a neocortical model of interictal 
spiking 
INTRODUCTION 
 Previous chapters have focused on interictal spiking in human epilepsy, and prior 
studies in our lab have implicated interictal spikes as having a potentially important role 
in epilepsy (31).  However, other studies both in humans (14,15,129) and in vitro [For 
review see: (130)] suggest that interictal spikes may actually even be protective against 
seizures.  To settle these discrepancies would require an animal model of chronic, 
neocortical interictal spiking.  At the start of this work, no such models existed.  Other 
models to study epilepsy typically focus on acute, severe seizures and have not been 
verified to act through the same molecular pathways as human epilepsy.  Not 
surprisingly, antiepileptic drugs developed using these models simply reduce the 
likelihood of seizures occurring, but do not correct the underlying brain abnormality that 
allows seizures to occur.  If a model of chronic interictal spiking could be developed and 
is shown to activate the same molecular pathways that are involved in human epilepsy, it 
would not only provide new insight into a poorly-understand phenomenon but also allow 
for the testing of novel, molecularly-targeted therapeutics.   
 In this chapter, we develop one such model.  Based on the work of Jeffreys on the 
tetanus toxin model of chronic epilepsy and the observation by Brener (60) that injection 
of tetanus toxin into the rat somatosensory cortex produces predominantly interictal 
spikes with minimal seizures, we focused on the use of tetanus toxin in the 
somatosensory cortex to create a model of chronic, neocortical interictal spiking.  Tetanus 
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toxin creates a focus of excitation by preferentially binding to gangliosides of inhibitory 
neurons, where it is taken up and prevents vesicle exocytosis through cleavage of 
synaptobrevin (VAMP-2) (61-63).  After determining an appropriate dose which 
generates frequent interictal spikes without observed seizures (131), we characterize how 
this spiking focus develops and progresses over time.  We show that a single injection of 
tetanus toxin produces a spiking focus which progresses in frequency and amplitude over 
time and that spikes progressively cluster together, weeks after the tetanus toxin is 
cleared from the brain.  We show that interictal spiking alone is enough to induce the 
activity-dependent gene expression changes seen in our human patients in some rats, and 
that these genes are activated in the same cortical layers as in human epilepsy.  Finally, 
after our work in human patients implicated the MAPK-CREB pathway as central to 
epilepsy, we demonstrate that a selective inhibitor of the activation of MAPK can prevent 
the development of a spiking focus.   
 
METHODS 
 
Surgery and electrode implantation 
 All studies were carried out with approval by Wayne State’s Animal Investigation 
Committee (AIC protocol A01-09-06).  Male Sprague-Dawley rats at four months old 
were kept on a 12-h light/dark cycle with free access to food and water.  Rats were 
implanted with recording electrodes and tetanus toxin was stereotactically injected as 
previously described with modifications (59,60). Rats were anesthetized with 
pentobarbital, placed in a stereotactic frame and holes were drilled in the skull over each 
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hemisphere at AP +4mm, -1mm and -6mm, L3.5mm relative to the bregma (Figure 4). A 
seventh hole was drilled at the midline over the nasal sinus. Tetanus toxin (Sigma, 
catalog# T3194) was reconstituted with sterile water to 100 ng/μL in 0.01M sodium 
phosphate and injected into the left somatosensory cortex (AP-1mm, L 3.5mm, as 
measured from bregma) at a depth of 1.5 mm over four minutes.  As tetanus toxin lots 
varied in potency, the dose injected was modified to produce the same amount of spiking 
when a new lot was purchased.  The rats used in the in situ hybridization time course 
(described below) received 65 ng, while all others in this study received 100 ng. The 
needle was left in place for 10 minutes to allow diffusion and binding of the toxin. Small 
screws were placed in each drilled hole and wired to a plastic connector to serve as 
electrodes, with the nasal sinus screw used as a common reference. For the in situ 
hybridization time course, parts were obtained from Plastics1 (Parts MS363 and E363), 
while for all other rats, the screws were from Small Parts, Inc (TX2-4-1C) and the 
connector from Molex (Part#0430450829).  Connector types did not have any discernable 
effect on any measurements made in this study.  The apparatus was secured with dental 
cement and the skin closed. Recordings were made using a 32-channel Stellate Harmonie 
system recording at 200Hz for one-hour periods at the same time of day over the course 
of three weeks. 
 
Evolution of the interictal spiking focus over time 
 To study the initiation and development of a chronic, neocortical interictal spiking 
focus over time, an initial group of tetanus-injected (n=7) and vehicle-injected (n=5) 
animals were followed over the course of three weeks.  The four 3-week time point rats 
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from the in situ hybridization time course described below were added to this initial 
dataset to give a total of 11 tetanus-injected rats for this study.  Recordings were 
reviewed in a referential montage (recording electrodes subtracted from the nasal sinus 
reference) and the location of spikes was marked manually by a single, blinded reviewer.  
Quantitative parameters about the spikes, including frequency, duration, amplitude, slope 
and field distribution on each recorded day were calculated for these marked locations 
using custom Matlab scripts (MathWorks, R2008b, Natick, MA).  For the measurement 
of spike clustering, spikes occurring within 500 ms of each other were considered 
members of the same spike cluster.  Three-dimensional plots of data on rat brains were 
generated using software developed for us by the Graphics and Imaging Lab (Dr. Jing 
Hua and Darshan Pai) of Wayne State University’s Computer Science Department.   
 
Activity dependent gene expression by in situ hybridization 
  Previous studies of human neocortex in our lab (10,31) suggested that interictal 
spiking may drive activity-dependent gene expression through CREB phosphorylation in 
human epilepsy.  To determine whether interictal spiking alone can drive activity-
dependent gene expression, groups of rats were sacrificed at multiple time points after 
initiation of a spiking focus and subsequently examined via in situ hybridization.  Four 
rats per time point were sacrificed at one week, two weeks and three weeks after tetanus 
injection, with an additional three surgery-naïve rats used as controls.  Each rat was 
sacrificed via a CO2 chamber and its brain was immediately dissected and fixed in 4% 
paraformaldehyde/PBS at 4ºC.  After subsequent equilibration in 30% sucrose in PBS, 
brains were cryosectioned at 20 μm.  In situ hybridizations were performed using 35S-
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labeled RNA probes as previously described (11). Full-length human cDNA clones 
(NARP: 5198692; BDNF: 5193877; GAPDH: 95132246CA2) or expressed sequence 
tags (EGR1: 6188360, truncated 3’ untranslated region) (Open Biosystems) were 
sequence verified and confirmed to share >=87% identity with the rat sequence.  Despite 
the availability of FANTOM clones (132), these clones were chosen because they had 
previously been used in our human neocortical sections and contained high sequence 
identity so that rat neocortical in situ hybridizations could be directly compared to the 
previous human ones.  Additionally, these clones had been tested previously in our rat 
sections and showed the expected distributions of signal, while antisense controls showed 
no signal.  Immunohistochemical staining for phosphorylated CREB was also performed 
on sections adjacent to those used for in situ hybridization. 
Prevention of interictal spiking focus development using a MAPK pathway inhibitor 
 Because the MAPK pathway was the pathway most strongly implicated in human 
epilepsy (10,11), we asked whether inhibition of this pathway could prevent the 
development of a spiking focus in the tetanus toxin model.  The compound SL327 was 
chosen for this study because it selectively inhibits a member of the MAPK pathway, 
mitogen-activated protein kinase kinase (MEK), in organotypic slice cultures, blocks 
ERK1/2 phosphorylation in a dose-dependent fashion and crosses the blood-brain barrier 
(133,134).  SL327 was obtained from Sigma-Aldrich (St. Louis, MO, catalog# S4069).  
First, a dosing regimen had to be determined because this compound had never been used 
in a chronic manner in any reported literature.  SL327 was dissolved in DMSO at a 
concentration of 25 mg/mL and injected intraperitoneally into three rats at a dose of 50 
mg/kg.  To determine plasma half-life and speed of brain penetration, the three rats were 
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sacrificed at 1 hour, 4 hours, and 24 hours after injection and their brains were removed 
and frozen at -80ºC.  Prior to sacrifice, blood samples were obtained via orbital bleeding 
at 15 minutes, 30 minutes, 1 hour, 4 hours 8 hours and 24 hours after injection up until 
the sacrifice time of each rat.  Blood samples were centrifuged at 800 g for 10 minutes 
and then frozen at -80ºC until the time of analysis.  Drug concentrations in all samples 
were determined using high-performance liquid chromatography with tandem mass 
spectrometric detection (HPLC-MS/MS) by our collaborator in Pharmacology, Dr. Jing 
Li.  Pharmacokinetic parameters such as terminal elimination half-life, volume of 
distribution and clearance were estimated using non-compartmental analysis in the 
software WinNonlin Professional 5.2 (Pharsight Corp., Cary, NC).   
 Once a dosing regimen that would maintain drug levels similar to those reported 
to be effective acutely had been determined, SL327 was tested for its ability to prevent 
CREB phosphorylation in vivo in our tetanus toxin model.  Four rats were given i.p. 
injections of 25 mg/kg SL327 dissolved at 25 mg/kg in DMSO twice daily for a week 
following tetanus injection, while another group of three rats were given only an 
equivalent volume of DMSO.  After one week, rats were sacrificed and their brains 
examined for CREB phosphorylation by immunohistochemical staining. 
 Once the ability of SL327 to prevent CREB phosphorylation in the tetanus toxin 
model was established, its ability to prevent the development of an interictal spiking 
focus was tested.  Three rats were injected with tetanus toxin and electrodes were 
implanted in the skull, as part of the usual protocol.  For the week following surgery 
though, they were each treated with SL327 and monitored for interictal discharges for a 
total of four weeks.   
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RESULTS 
 
Spikes increase in frequency, amplitude and slope over time 
 The injection of tetanus toxin into the rat somatosensory cortex successfully 
generates ‘interictal’ discharges with no initiating seizure.  Spikes can be detected on 
EEG starting around days three to five after injection, and then increase in frequency with 
time (Figure 5A).  Vehicle animals show significantly less spiking at the first week 
(p=0.029, one-tailed t-test, Bonferroni correction; 79.1±18.1 and 9.4±2.9 spikes/ hour, ±  
sem), which persists at two weeks (p=0.020, one-tailed t-test, Bonferroni correction; 
101.3±19.5 and 9.5±2.9 spikes/ hour, ±  sem) and three weeks (p=0.040, one-tailed t-test, 
Bonferroni correction; 178.33±45.3 and 8.6±4.2 spikes/hour±sem). Spike amplitude 
increases initially, but then appears to plateau by 10 days (Figure 5B; Best fit model: 
y=a*xb+c; R2=0.667).  Spike slope increases progressively with time (Figure 5C; 
R2=0.530; Linear regression slope=0.307μV/day, p=0.0004), while duration does not 
appear to change (Figure 5D; R2=0.148; Linear regression slope=-0.299ms/day, 
p=0.104).   
 
Spike clustering 
 Spikes were observed to progressively cluster together over time (Figure 6).  
While spikes initially appeared as individual, isolated discharges, ‘doublets’ often 
appeared by a week after injection and became progressively more common.  As time 
went on, longer runs appeared and became more common, so that by three weeks over 
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30% of the spikes in a recording occurred clustered with other spikes (R2=0.492;  Linear 
regression slope=0.75%/day, p=0.0025).  A single animal with frequent repetitive bursts 
was also observed to develop a focal seizure from this focus, but the exact relationship 
between spike clustering and seizures cannot be drawn from this data, given that long 
term recordings were not part of this project. 
 
Spike field expansion 
 The placement of six epidural recording electrodes allowed us to not only detect 
interictal discharges, but to track their electrical field and spread over time (Figure 7).  
Rats varied in their patterns of field expansion so that while most were restricted to the 
injection site and left anterior electrode (Figure 7A,B), a small number of rats developed 
a spiking focus restricted to the right hemisphere, contralateral to the injection site 
(Figure 7C,D).  This finding is consistent with other studies using tetanus toxin in 
hippocampi, where injection in one hemisphere sometimes leads to epileptic activity 
initiated in the opposite hemisphere (60,135).  Combining all surveyed rats together, 
however, shows that the most common pattern of expansion was to begin with small 
spikes at the injection site, spread to involve the left anterior electrode, and then 
eventually involve the right middle electrode (Figure 7E).  Interestingly, spikes never 
spread posteriorly from the injection site, suggesting that the pattern of interictal spike 
spread is closely related to normal anatomic barriers that separate cortical areas of 
different function. 
 
Activity-dependent gene expression 
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 Previous results from our laboratory showed that activity-dependent gene 
expression changes correlate with interictal spiking.  Further, these expression changes 
could be localized to specific lamina of the neocortex, predominantly layers II and III.  
To ask whether interictal spiking alone could induce changes in activity dependent gene 
expression, we performed in situ hybridizations on multiple animals sacrificed at one, 
two and three weeks after tetanus toxin injection.  The genes examined in this study were 
chosen because they had all been previously shown as robustly differentially expressed in 
human epilepsy and represented several different functional categories.  Egr1 and Bdnf 
are immediate early genes (136-141)  and Narp (Nptx2) clusters AMPA-type glutamate 
receptors at excitatory synapses (142,143).  
   Three of the four animals sacrificed after one week of spiking showed a small 
region of suppression at the injection site, with one also showing a focus of strong gene 
induction at the center (Figure 8).  This focus showed Egr1, Narp, and Bdnf expression in 
exactly the same area on adjacent sections.  This pattern was virtually identical to the 
pattern of Egr1 protein distribution in another study using tetanus toxin in the motor 
cortex (144).  By two weeks, rats that were sacrificed during a time of recent increases in 
spike frequency and amplitude showed increased gene expression in the left, spiking 
hemisphere than the right, non-spiking hemisphere.  By three weeks, however, most rats 
had stabilized in spike frequency and/or amplitude and no longer showed lateralized 
differences in gene expression, even when spike field was well-restricted to one 
hemisphere.  Normal, surgery-naïve rats and 0.01M vehicle-injected rats showed even 
hemispheric gene expression throughout, and antisense probes showed no signal.   
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 In rats with lateralized gene expression changes, these changes were consistently 
in layers II/III of the neocortex, just as we previously found in human epileptic tissue 
(10,11).  Egr1 generally filled layers II and III, while Narp and Bdnf were restricted to 
thin bands in the superficial part of layer II.  Again, these results parallel our previous 
findings in human neocortex.  Despite the varying patterns of expression in the rats 
surveyed, all rats were internally consistent in that all the genes detected were 
upregulated in the same areas as the others on adjacent sections.   
 
MAPK pathway inhibition prevents the development of a spiking focus 
 MAPK-CREB signaling was by far the pathway most implicated in the human 
epileptic transcriptome (10,11), so it seemed a logical target for therapeutic intervention 
in our animal model.  In this experiment, we therefore determined a dosing regimen for 
the MAPK pathway inhibitor SL327, verified that it was able to prevent CREB 
phosphorylation after one week of treatment, and then tested its ability to prevent an 
interictal spiking focus from developing.  One week after the induction of a spiking 
focus, CREB is usually phosphorylated in the left, spiking hemisphere relative to the 
right, non-spiking one (Figure 9A; n=5/7 rats).  Using plasma and brain concentrations of 
SL327 over time (Figure 9B), Dr. Jing Li calculated the half-life to be 6.8 hours and 
recommended dosing the rats twice daily with 25 mg/kg.  Rats treated with this dose for 
one week following tetanus toxin injection showed markedly reduced CREB 
phosphorylation relative to DMSO-injected controls (Figure 9C).  Treatment of rats with 
SL327 during the first week after tetanus injection significantly reduced spiking rate 
(Figure 9D) by the first week (p=0.005, one-tailed t-test, Bonferroni correction; 79.1 ± 
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18.2 and 7.0 ± 3.6 spikes/ hour, ±  sem) that persisted at 2 weeks (p=0.044, one-tailed t-
test, Bonferroni correction; 100.5 ± 27.3 and 18.0 ± 9.0 spikes/ hour, ±  sem) and 3 weeks 
(p=0.013, one-tailed t-test, Bonferroni correction; 178.3 ± 45.3 and 30.7 ± 7.6 spikes/ 
hour, ±  sem), suggesting that MAPK is necessary for the development of interictal 
discharges.  SL327 treated animals did not significantly differ from vehicle animals at 
any of these time points.  
 
DISCUSSION 
 
Interictal spikes may be a precursor for epilepsy and seizures 
 In this chapter, we characterized a rat model of chronic, neocortical interictal 
spiking for the first time.  The advantages of this model are that it is essentially ‘non-
lesional’ in that it does not cause the extensive neuronal loss and gliosis associated with 
other models like kainic acid and pilocarpine, and it has a chronic time course that better 
parallels the development of human epilepsy (55,56,145,146).  Spikes develop after an 
initial latent period of several days and then steadily progress in frequency and amplitude 
with time, despite tetanus toxin being cleared from the brain by then (147).  This implies 
that once initiated, a spiking focus is both self-sustaining and expands over time.  
Combining this observation with the fact that spikes progressively cluster together with 
time raises the intriguing hypothesis that interictal spikes may be an essential precursor to 
seizures and an integral part of epileptogenesis (148).  This conclusion is supported by a 
recent study which shows that both the frequency of interictal spikes and the presence of 
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spike clusters predict which animals will develop spontaneous seizures following status 
epilepticus in the hippocampal kainic acid model (149). 
 
 
Layer-specific changes in activity-dependent gene expression are associated with 
interictal spiking 
 Interictal spikes without observed seizures were able to induce activity-dependent 
gene expression changes in genes previously confirmed to be upregulated in human 
epileptic foci.  All changes in gene expression were observed in layers II and III of the 
cortex, exactly as we have seen in our previous human studies and in contrast to most 
other work in animal models of epilepsy (42).  Not all rats showed lateralized gene 
expression changes consistent with lateralized spiking, but those that did were the 
animals that were increasing in frequency and amplitude at the time of sacrifice, which 
may mean that only neurons undergoing active remodeling show detectable differences in 
these plasticity-associated genes.  No rats showed expressed changes opposite their spike 
field and surgery-naïve rats all showed homogenous gene expression.  EGR1 (150-152) 
and BDNF (153) are regulated by CREB, and while the control of NARP transcription 
has not been well studied, its promoter contains a CREB binding site (154,155).  While 
additional work beyond these initial studies needs to be done, these results so far imply 
that this model may be an accurate representation of human epilepsy at the molecular 
level and that targeted therapeutics developed in this model are likely to translate well 
into human use. 
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MAPK-CREB pathway inhibition and drug development 
 In this study we showed that a MAPK pathway inhibitor can reduce CREB 
activation and prevent the development of an interictal spiking focus.  These results 
support our conclusions from the human epileptic transcriptome, which implicated 
MAPK-CREB signaling and present the exciting possibility that entirely novel 
therapeutics for epilepsy can be developed.  It has been shown that constitutive activation 
of ERK, the kinase blocked in this study, causes epilepsy (156) so blocking its activity 
may be an effective treatment of epilepsy, or at least prevent its development after injury.  
A recent study showed that current antiepileptic drugs block seizures, but do not prevent 
spike activity in vitro (157).  Since results from our studies suggest a role for interictal 
spikes in epilepsy and epileptogenesis, new therapies that target interictal spiking may be 
more effective at treating epilepsy than current medications only treat seizures. 
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CHAPTER 5 
Behavioral consequences of interictal spiking in a rat model 
INTRODUCTION 
 Epilepsy is a disease of recurrent seizures, with most research attention over the 
years focusing on the seizures themselves.  While seizures are often the major cause of 
morbidity for patients, patients with epilepsy also suffer from a wide range of comorbid 
brain disorders, not always linked directly to seizures.  For example, estimates of 
attention-deficit hyperactivity disorder (ADHD) in children with epilepsy range from 20-
40%, while the incidence in the general population is only 3-7% (66-72).  Patients with 
epilepsy are also more likely to have depression (68,73-78), anxiety disorders 
(68,73,75,77-79), and other psychiatric conditions (68,71,78-82).  Given that seizures 
occur infrequently and that most of a patient’s life is spent in the interictal state between 
seizures, it is conceivable that these comorbid conditions are better related to a process 
going on between seizures, rather than the seizures themselves.  Interictal spikes would 
be a prime candidate for this abnormal process. 
 Outside of the increased comorbidities in patients with epilepsy,  interictal spikes 
have also been associated with most of these conditions in the absence of an epilepsy 
diagnosis as well.  Interictal discharges have been most strongly linked to children with 
ADHD, even in the absence of epilepsy (158-163).  Several other studies have linked 
epileptiform discharges to a variety of other psychiatric ailments, including depression, 
anxiety disorders, and obsessive-compulsive disorder (84-86).  With all the evidence 
linking interictal discharges to behavioral and psychiatric disorders, an animal model of 
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chronic interictal spiking without seizures may provide insights into these disorders and 
allow them to be studied in vivo in a way not previously possible. 
 In Chapter 4 we showed that the tetanus toxin model of interictal spiking can 
reliably produce spikes without seizures.  Additionally, it shows induction of several 
activity-dependent genes in a similar pattern found in human epilepsy, suggesting that 
this model may also be a good model to explore comorbidities.    In this chapter we 
demonstrate that our animal model of interictal spiking leads to specific behavioral 
abnormalities.  We also demonstrate for the first time that interictal spiking can be 
induced by environmental stimuli in animals with an epileptic focus.  We show that 
spiking rats are more active, that the level of their activity correlates with their level of 
spiking on a day-by-day basis, and that lateralized spikes cause lateralized movements.  
Suppression of interictal spiking with a MEK inhibitor normalizes these behaviors.  
These studies not only raise important questions on the significance of interictal spiking 
in patients with epilepsy, but also provide a novel animal model to develop novel 
pharmacological treatments for interictal spiking that could also have important effects 
on behavior.   
 
METHODS 
 
Open-field activity measurements 
Rats underwent the same surgical procedure and tetanus toxin injection to initiate 
neocortical interictal spiking as described previously in Chapter 4.  Four tetanus-injected 
and four sham-operated (electrodes implanted, but no injection into brain) animals were 
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followed over time to measure the effect of progressive interictal spiking on open-field 
activity.  Immediately after EEG was recorded for one hour, rats were placed in an open-
field activity chamber (ENV-515, MedAssociates, Inc., St. Albans, Vermont) for an hour, 
which uses an array of infrared beams to track movement.  The included Activity 
Monitor software was used to calculate total ambulatory distance over each one-hour 
recording period.   
To examine the effect of focal interictal spiking on behavior in more detail, a 
group of seven tetanus-injected animals were placed in the open-field activity chamber 
immediately following an EEG recording session.  The ratio of the number of spikes 
from the left hemisphere to the number of spikes in the right hemisphere as well as total 
spike power (frequency * amplitude) were compared to the ambulatory distance, resting 
time, and the ratio of counter-clockwise to clockwise rotations, as calculated by the 
Activity Monitor software.  For these comparisons, the numbers within each rat were 
converted to Z-scores so that data from multiple rats could be combined together for an 
overall correlation.    
 
Auditory evoked interictal spikes 
 To measure the effect of a startle evoked by an auditory stimulus, a total of 11 
spiking rats and five vehicle rats were monitored over time for their response on EEG to a 
repeated stimulus.  To induce spikes in a reproducible manner, a digital audio recording 
of a single clap was made.  While EEG was being recorded, this sound was played in the 
recording chamber three times at intervals of 10 minutes apart, followed 10 minutes later 
by a train of three repetitions, each one second apart (Figure 11A).  Responses were 
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marked on the EEG files and spike amplitude in each channel was calculated using a 
Matlab script.  The response to the three claps spaced 10 minutes apart were averaged 
together for each day as a measure of response magnitude at each time point, while the 
train of spikes was considered separately to measure extinguishment of the response. 
 
Effect of suppressing interictal spikes on behavior 
From the results in Chapter 4 that showed that SL327, a selective MEK inhibitor, 
can prevent the development of a spiking focus, we hypothesized that this suppression 
could normalize behavior in tetanus-injected rats.  Five tetanus-injected rats, four vehicle-
injected rats, and three rats who received tetanus toxin followed by SL327 for one week 
after surgery were followed over time to measure the effect of progressive interictal 
spiking on open-field activity.  While EEG was being recorded for one hour, rats were 
placed in the open-field activity chamber and monitored for ambulation distance over 
time. 
 
RESULTS 
 
Interictal spiking increases rat motile behavior 
 As a first step, we determined the ambulatory behavior of rats with progressive 
increases in interictal spiking after tetanus toxin injection into somatosensory cortex.  
Infrared measurements of ambulatory mobility performed daily showed that interictal 
spiking is associated with a significant increase in rat ambulation, leading to what could 
be termed a ‘hyperactive’ rat (Figure 10A).  The average ambulatory distance of spiking 
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rats was greater than that of sham controls at all time points measured, and showed the 
most divergence toward the end of the three week period when tetanus-injected rats were 
at their maximal spiking (1 week: p=0.082, 7946.5±851.0cm versus 5605.7±759.4cm; 2 
weeks: p=0.079, 7808.2±1046.1cm versus 5501.3±571.3cm; 3 weeks: p=0.0005, 
8610.0±733.8cm versus 4668.0±504.5cm;  distance±SEM, all p values after Bonferroni 
correction). 
 Next, we looked in more detail at the relationship between interictal spiking and 
movement parameters.  For seven rats followed either for two weeks (n=3) or three 
weeks (n=4), spiking was measured for one hour immediately prior to placing the rat in 
the open field activity chamber for one hour.  The ratio between the number of spikes 
originating in the left hemisphere versus the number originating in the right hemisphere 
correlated significantly with the ratio between the number of counter-clockwise  and 
clockwise rotations the rats made (Figure 10B;  R=0.396, p=0.013 Bonferroni 
correction).  This result means that more interictal spikes on a rat’s left caused it to rotate 
more frequently counter-clockwise to its own left side, while right-sided spikes are 
associated with clockwise rotations.  Total spike power correlated positively with 
ambulatory distance (R=0.350, p=0.039 Bonferroni correction) and negatively with 
resting time (R=-0.410, p=0.008 Bonferroni correction).  Therefore, not only are 
interictally-spiking rats hyperactive as a group relative to control animals, but within just 
spiking rats the level of their activity varies with the level of spiking on that day. 
 
Startle-induced spikes occur in same field as spontaneous spikes 
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 A startling auditory stimulus, such as a clap in this case, consistently evokes an 
interictal spike in rats that are already spiking.  The field of the spike induced is always 
the same as each rat’s individual spontaneous spike field.  Figure 11B shows an example 
rat that has spontaneous spikes originating predominantly under the middle, left electrode 
(L2) with a small contribution in the contralateral electrode (R2).  When this rat is 
startled, the induced spike occurs with the exact same distribution, although with a 
slightly higher amplitude.  As an illustration of a rat with an entirely opposite field, 
Figure 11C shows a rat which has spontaneous spikes originating from the right, middle 
electrode (R2).  Predictably, the spikes induced by an auditory stimulus in this rat are 
restricted to the same electrode, but again at slightly higher amplitude than the average 
spontaneous spike.  Every tetanus-injected rat showed this correspondence between 
spontaneous and induced spike fields, while vehicle rats did not have a response on EEG 
when startled. 
 Not only do induced spikes have an identical field as each rat’s spontaneous 
spikes, but the response changes with time as the spiking focus changes.  As the average 
amplitude of a rat’s spontaneous spikes increases over time, so too does the average 
amplitude of the induced spikes.  Figure 11D shows the correlation between average 
spontaneous and induced spike amplitudes over time, measured at the channel of 
maximum amplitude in each rat and normalizing amplitudes in each rat so that the 
maximum value is 100% (R=0.535, p=1.42x10-9).   
 The EEG response of induced spikes seems to depend on the rat being genuinely 
startled.  When the recorded claps are spaced only one second apart instead of 10 minutes 
apart, the response extinguishes rapidly (Figure 11E).  The first response was 
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significantly larger than the response to the second stimulus (650.2±40.0μV versus 
273.1±43.4μV; p=8.1x10-9, Bonferroni correction; amplitude±SEM) and the response to 
the third stimulus (650.2±40.0μV versus 156.2±28.7μV; p=1.1x10-21, Bonferroni 
correction; amplitude±SEM).  The second and third responses did not significantly differ 
after correcting for multiple comparisons (273.1±43.4μV versus 156.2±28.7μV; p=0.079, 
Bonferroni correction; amplitude±SEM).  Anecdotally, a sudden, unexpected touch on 
the rat’s back can also induce an EEG spike when the rat is startled.  While this was not 
possible to repeat in a consistent enough manner to quantify, it suggests that the response 
observed in this study is not a unique feature of the auditory system, but more likely 
represents a startled response to any stimulus. 
 
Suppression of interictal spiking normalizes behavior 
 To show that interictal spiking truly alters rat behavior, tetanus-injected rats were 
compared to rats who received both tetanus toxin and a selective MEK inhibitor that 
prevents the development of a spiking focus.  Pooling ambulation data for weeks one, 
two and three after surgery shows that while tetanus-injected rats increase in ambulatory 
distance over time, rats treated with the MEK inhibitor SL327 for one week after tetanus 
injection (same as those described in Chapter 4) remain about the same (Figure 12).  In 
contrast to the ambulatory measurements described previously in this chapter, these rats 
were monitored for ambulation while simultaneously having EEG recorded.  Therefore, 
the presence of the recording tether reduced overall movement distance, accounting for 
the vastly different scaled between Figure 10A and Figure 12.  The two groups do not 
differ in the first week (p=0.645, t-test, Bonferroni correction; 1144.5±197.3cm and 
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711.8±293.8cm), but by the second week the spiking animals were moving more than the 
SL327 treated ones (p=0.025, t-test, Bonferroni correction; 1205.4±127.9cm and 
627.7±150.5cm).  By the third week, the two groups had diverged widely (p=0.012, t-test, 
Bonferroni correction; 1692.6±193.3cm and 759.0±223.1cm).  Vehicle animals showed 
no increase over time and ambulated almost exactly as much as the SL327-treated 
animals (729.4±93.2cm). 
 
DISCUSSION 
 
Interictal spiking causes hyperactive movement 
 In this chapter, we showed that spiking rats are hyperactive relative to sham-
operated control rats.  This result is especially interesting in the context of reports 
showing that ADHD is frequently associated with epilepsy and that interictal discharges 
are more common in children with ADHD than normal children, even in the absence of 
epilepsy.  More spiking was also associated with more ambulation and less resting time 
on a day-by-day basis.  Again, these results strengthen the conclusion that interictal 
spikes directly cause the observed changes in behavior.  Further, location of the interictal 
spiking focus caused asymmetric ambulation in spiking rats.  The ratio between left and 
right hemispheric spikes was correlated with the ratio between counter-clockwise and 
clockwise rotations, meaning that as the number of spikes originating from the left 
hemisphere increased, so too did the number of counter-clockwise rotations.  Since 
tetanus toxin was injected into the left somatosensory cortex, it is possible that interictal 
spikes in this region caused the rat to feel a negative sensation on the right side of its 
51 
 
body, and then turn away from it.  Therefore, not only does the presence of interictal 
spikes affect behavior, but the type of behavior observed appears to depend on their 
location.  These are the first in vivo results showing an effect of neocortical interictal 
spiking on behavior, and together suggest that the tetanus toxin model of neocortical 
interictal spikes may be able to offer insights into a range of psychiatric disorders where 
interictal spikes have been observed.   
 
Environment can influence interictal spiking 
 Next, we demonstrated that interictal spikes can be induced in spontaneously-
spiking rats by a startling sound.  Further, these induced spikes always occur in the same 
field distribution as each rat’s spontaneous spikes, implying that the same population of 
hypersynchronized neurons is likely being activated in both cases and that these neurons 
are more easily brought to threshold than normal neurons.  This is perhaps the first 
observation that a common environmental stimulus such as sound can alter interictal 
activity in vivo. 
 
Suppression of interictal spiking normalizes behavior 
Finally and perhaps most importantly, we showed that treatment with a MEK 
inhibitor during the first week following tetanus injection prevented the hyperactivity 
seen in the spiking rats.  While it is true that the drug itself could reduce rat movement by 
negatively impacting their health, this effect would be expected to cease once treatment 
stopped in the first week.  By the third week any residual drug effects are gone and rats 
have returned to their normal health state, yet SL327-treated rats show no increase in 
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ambulation at this time.  Instead, their total ambulation remained constant throughout the 
monitoring period and was essentially identical to that of the non-spiking vehicle rats.  
Together, these results imply that interictal spiking itself is directly responsible for the 
increased activity and that this effect can be mitigated with a selective molecular 
inhibitor.  While this study has only explored the prevention of a spiking focus with a 
MAPK pathway inhibitor, MAPK inhibition should be explored as an entirely new 
therapeutic strategy for a variety of psychiatric disorders with epileptiform abnormalities. 
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Chapter 6 
Discussion 
 
Quantitation of interictal spikes to improve surgical outcome and advance research 
 In Chapter 2 we demonstrated that professional electroencephalography (ECoG) 
reviewers varied widely in their detections of interictal spikes.  Such variation could lead 
to subjective clinical decisions and make it difficult to compare results between research 
studies on interictal spikes.  This may explain why there have been mixed results in the 
use of interictal spikes to identify the seizure onset zone and improve surgical outcome 
(16-23).  Due to the tremendous variation in spiking rates over time within patients(17) 
and the frequency of spikes on ECoG, manual marking of interictal spikes is simply not 
feasible as regular, reliable method of quantifying ECoG.  While many other algorithms 
for spike detection have been published (for review see: (122)), only a few have been 
verified on intracranial recordings (29,121,123,124) and these have either only examined 
single channels or verified spikes already detected by humans.  Here, we showed that our 
method can be run on full ECoG recordings and still preserve differences in activity 
between channels.  Additional benefits to this method are that it requires no changing of 
parameters for each patient, runs very quickly, and is fairly simple to implement.   
 We subsequently used this spike detection algorithm to see if other parameters 
besides spike frequency could be used to identify regions of seizure onset.  We 
determined that brain areas which either generate or participate in seizures cannot be 
distinguished from each other based on these interictal spike parameters, but that these 
epileptic regions differ from control regions.  In this group of non-lesional patients, the 
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parameters examined did not significantly improve upon spike frequency for the 
identification of seizure onset zones, but several characteristics of spikes did perform 
equally well.  In the future, it might be possible to show that different parameters do a 
better job with different patients.  For example, spike morphology might be affected by 
disease duration, initiating etiology, antiepileptic medications, or functional area of the 
brain in which it occurs.  With a larger sample of patients, it may be possible to stratify 
patients into groups and find which parameters of spike morphology best fit each 
subpopulation. 
 The use of ECoG in tumor surgery patients provided new and interesting results, 
since this method is rarely used in tumor surgeries.  Here we found that the spiking 
parameters which best identify seizure onset zones in lesional patients are different than 
those found in non-lesional patients.  In this group of tumor patients, frequency was not 
the best measure of seizure onset areas; duration of the second halfwave was a much 
better marker.  More surprisingly, we found that seizure onset areas regularly lie outside 
of the immediate tumor area, and that increasing spike frequency was actually correlated 
with increasing distance away from the tumor.  These results suggest that the use of 
ECoG in tumor patients with comorbid epilepsy may give valuable additional 
information to the surgeon.  An expanded group of patients followed after surgery for 
post-operative outcomes will eventually answer whether there is a true clinical advantage 
to using ECoG data in these tumor resections and for which types of patients it is most 
helpful. 
One problem in the world of spike detection is that techniques are developed and 
papers are published, but then no one but the authors use the algorithm that they 
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developed.  Widespread adoption of this algorithm could be facilitated by integrating it 
into a broader set of tools.  Now that we have developed and verified an automated 
method of spike detection, a whole host of research questions can be asked about the 
relationship between interictal spikes and epilepsy which would have been impossible to 
do in an objective, efficient manner previously.  The next steps in development could be 
to integrate it into ECoG recording software so that detections can be made in real time, 
and then include new quantitation and visualization tools.  We are currently working with 
Dr. Jing Hua in the Computer Science department to be able to display spike detection 
results on a three-dimensional image of a patient’s brain in real time.  This would allow 
clinicians and researchers to visualize how groups of electrodes are linked to each other, 
whether spikes in one area lead and perhaps drive spikes in another area, and determine 
how spiking patterns change with time or patient activity.   
 
Interictal spikes in epileptogenesis 
 In Chapter 3, we described the development and characterization of an animal 
model of chronic, neocortical interictal spiking.  In this model, a single injection of 
tetanus toxin is followed by a latent period of several days before spikes are first 
detected.  Spikes then increase in frequency, amplitude, electrode involvement and 
clustering with time, even after the initial insult (tetanus toxin) is gone.  This pattern 
mirrors the development of acquired epilepsy in humans, although on a shorter time 
scale.  The latent period before seizure development in humans can range from months to 
years after the initial insult (1,55,56).  The absence of an initiating seizure in this model 
allows the effects of in vivo interictal spiking to be isolated, and the increase with time 
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shows that they are not benign.  In fact, the progressive clustering of spikes may 
represent the process that takes place during the latent period before clinical seizures in 
human epilepsy.  More frequent and longer clusters of spikes indicated that the brain is 
changing with time in a way that allows faster recovery from a massive depolarization 
and the ability to depolarize again more quickly.  As a focal seizure is often arbitrarily 
defined as lasting for 10 seconds (164), a sufficiently long train of interictal spikes would 
be indistinguishable from a focal seizure, and likely represents a transition from single 
interictal spikes to electrographic seizures.  Recent work in the kainic acid model of 
hippocampal epilepsy supports the role of interictal spikes in epileptogenesis.  White, et. 
al. demonstrated that after kainic acid-induced status epilepticus, interictal spikes appear 
before spontaneous seizures (149).  Further, increasing spike frequency and increasing 
spike clustering were predictive of which animals would develop convulsive seizures in 
the future.  Our work adds to this study and shows a similar pattern of spike progression, 
but without any initiating seizure and in an entirely different animal model. 
 Data from our laboratory’s work in human epilepsy showed CREB 
phosphorylation and activity-dependent gene expression predominantly in layers II/III of 
the neocortex (10,11).   Initial work in the tetanus toxin model of neocortical interictal 
spiking agrees with these findings, which both supports the validity of our human 
findings, as well as the use of the tetanus toxin model as a molecularly-accurate model.  It 
is important to note, however, that only 57% of canonical cyclic AMP response elements 
(CREs; sequence TGACGTCA) are conserved between human and rat, so the two species 
may exhibit somewhat different transcriptional profiles (165).  Further characterization 
therefore needs to be done in order to be certain that this animal model sufficiently 
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replicates the human disease.  The significance of layers II and III is that these are the 
layers primarily responsible for lateral, associative communication with other cells of the 
cortex (166).  It is conceivable therefore that that the spiking focus expands through these 
lateral connections.  Under this model, an initially small focus of hyperexcitability is 
created by some initial lesion (human patients) or tetanus toxin’s cleavage of 
synaptobrevin (167) (rat model).  The affected neurons would signal excessively on the 
‘neighbors’ they are connected to, which would induce activity-dependent pathways in 
these neurons and cause them to become synchronized with the original group (see 
Figure 13 for schematic of MAPK pathway’s proposed role in this model).  Continued 
spiking could expand the focus in a similar matter until a large population of neurons in 
the superficial cortical layers has become excessively synchronized, and spikes can be 
detected as field potentials.  Further alterations in synaptic efficacy and recovery times 
could lead to the generation of clustered spikes and eventually seizures.  
 Further studies would be required to prove this hypothesis.  First, the results from 
in situ hybridizations presented in Chapter 3 showed changes in gene expression only in a 
subset of animals which were undergoing increases in spike frequency and amplitude at 
the time of sacrifice, while most animals showed no lateralized changes, even if spikes 
were frequent and well-restricted to one hemisphere.  These data lead us to the hypothesis 
that activity-dependent gene expression in this model can only be detected while neurons 
are actively undergoing synaptic plasticity and long-term potentiation.  To confirm this 
hypothesis, instead of deciding to sacrifice rats at an array of time points as was done 
here, rats should be continually monitored for spiking parameters and sacrificed during 
periods of rapid increase.  The initial work on the tetanus toxin model of neocortical 
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interictal spiking presented here demonstrates that individual rats vary widely in the rate 
of progression of their spiking focus, so that it will be more logical to group rats by 
observed spiking parameters than to attempt to group them by arbitrary time points.  This 
method may more consistently reveal the link between activity-dependent gene 
expression and interictal spikes in this model. 
 Finally, one of the most important studies to next be carried out in this model will 
be to examine the progression from interictal spikes to seizures.  We recently installed 
equipment for continuous EEG monitoring of rats, so we can now follow rats constantly 
and determine when seizures first develop in this model.  This will hopefully allow us to 
determine which variables, such as spike clustering, are most important for the 
progression from interictal spikes to seizures.  We would also be able to sacrifice rats that 
have just developed seizures and ask how they differ at a molecular level from rats who 
do not have seizures.  In fact, it may be prudent to categorize rats into non-spiking, 
individual spiking, clustered spiking, and seizures to see if different signaling and 
transcriptional profiles are activated in each.  For example, blocking Phospholipase C in a 
hippocampal slice culture model is able to prevent the initiation of interictal spiking, but 
not the continuation of spiking once it has been established (168).  Protein Kinase C 
(PKC) activation, on the other hand, is able to convert single interictal discharges to 
clustered bursts of spikes in guinea pig hippocampal slices (169). 
 
Behavioral changes of the interictal state 
In Chapter 5, we showed that interictally-spiking rats exhibit several behavioral 
changes.  These observations are important in light of the numerous conditions comorbid 
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with epilepsy (66-82), and the observations of spikes in a broad array of psychiatric 
disorders as described previously (158-163).  We first observed that interictal spikes 
could be induced by a simple, external stimulus such as a clap.  The field of the induced 
spike was identical to each rat’s spontaneous spikes and its amplitude varied with 
spontaneous spikes amplitude as well, strongly suggesting that the same group of neurons 
is involved in both cases.  Given the old adage among epileptologists that “seizures beget 
seizures” (170,171), it may also be true that spikes beget spikes, in which case this study 
could have implications for how epileptic patients should be treated.  To test this 
hypothesis, groups of rats could be set up in parallel, where one group is subjected to 
random, startling sounds while the other group is not, and spontaneous spike frequency 
could be monitored over time.  Given the innate variability in this model, however, a 
large number of rats would need to be used in order to detect differences in spiking with 
sufficient power. 
The next major result is that rats with interictal spiking are hyperactive relative to 
non-spiking controls.  This is a very significant observation, as interictal spikes are still 
often considered symptomatically benign, despite the associative studies in psychiatric 
literature.  Neocortical interictal spikes without seizures have never been previously 
shown to have behavioral effects in an animal model.  The only other studies showing an 
effect of interictal spikes on behavior or cognition in animal models were just published 
this year.  One that showed hippocampal spikes impaired memory retrieval and response 
time to tasks (172) and another showed that hippocampal spikes during neonatal 
development impaired reference memory and long-term potentiation in these rats as 
adults (173).  Finally, we observed that spiking rats turned counterclockwise more often 
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than clockwise in proportion to the number of spikes originating from the left versus right 
hemispheres on the day of recording.  Therefore, the location of the interictal spike 
actually influences the behavior displayed.   
Taken together, these results argue for a potential role of interictal spikes in the 
comorbidities of epilepsy or psychiatric disorders.  It may therefore be beneficial to treat 
not only seizures, but also interictal spikes in epilepsy patients experiencing comorbid 
conditions, and to look for the presence of interictal spiking more often in psychiatric 
patients.  The tetanus toxin model described here provides a new animal model in which 
hypotheses and eventually treatments for these human ailments can be tested.   
 
MAPK pathway inhibition as a new therapeutic for epilepsy  
 The role of the MAPK pathway in epilepsy, especially ERK, has been implicated 
by both human (174,175) and animal studies (176-180).  In fact, conditional expression 
of a constitutively active form of ERK in rats was shown to cause epilepsy, 
demonstrating that ERK activation alone is sufficient to cause the disease, at least in an 
animal model (156).  Transcriptional analysis by microarrays in our laboratory has 
provided the strongest evidence to date that MAPK activation is central to human 
epilepsy (10,11).  Components of the MAPK pathway were greatly enriched in the 
epileptic transcriptome, and a transcription factor binding site search revealed that the 
downstream target, CREB, was enriched over the next factor (serum response factor) by 
several orders of magnitude.  Therefore, when creating an animal model of epilepsy, we 
expected to find evidence of MAPK-CREB activation and then to subsequently test 
inhibitors of this pathway as possible treatments.  Frustratingly, this was difficult to 
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demonstrate consistently in spiking rats either by western blot or immunohistochemistry.  
This difficulty may be due to the labile nature of MAPK activation after a stimulus in 
neurons (181,182).  Regardless, CREB phosphorylation was greater in layers II and III of 
the spiking hemisphere in most animals sacrificed one week after tetanus injection, 
implying that at least initially it corresponds well to the location of spike activity.   
More conclusive, however, was the use of SL327, a compound which selectively 
inhibits the phosphorylation of ERK by MEK (133,134).  SL327 administered to rats in 
the first week following tetanus toxin injection prevented the development of a spiking 
focus, providing strong evidence that ERK activation is required for initiation of this 
process.  This inhibitor was also able to prevent the increase in ambulation associated 
with the development of interictal spikes, even weeks after it was discontinued.  The next 
step will be to see whether treatment with this drug once a spiking focus has already been 
established will be able to reduce or abolish interictal spiking, or more importantly, to 
prevent the development of seizures.  If effective, this would represent an entirely new 
avenue of therapy for epilepsy, one which could hopefully correct the underlying brain 
abnormality itself, rather than simply reduce the symptom of seizures.   
 
Other therapeutic targets 
 The MAPK pathway inhibitor used here was chosen because it could be given 
simply through an intraperitoneal injection yet still penetrated the brain, and had been 
shown to be effective at knocking down ERK and CREB phosphorylation in rat brain in 
vivo (133,134).  It is certainly not the only option for targeting this pathway though, and 
perhaps administration of an inhibitor that does not cross the blood-brain barrier through 
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an intracranial cannula would allow higher concentrations to be used without the side 
effects of systemic MAPK inhibition.  Recent unpublished data from our laboratory 
(Bagla S, Brown E, Barkmeier D) suggest that phosphorylated p90-Ribosomal S6 Kinase 
is a more reliable marker of epileptic brain areas than either dpERK or pCREB, so it may 
actually make a better target for inhibition. 
 Outside of the MAPK pathway, other signaling cascades may also prove to be 
effective therapeutic targets.  Serum Response Factor, for example, plays a role in 
activity-dependent plasticity (183-185) and was the second most enriched transcription 
factor in our human epileptic transcriptome after CREB.  The activation states of other 
pathways classically associated with activity-dependent plasticity such as Protein Kinase 
A, PKC and Calcium-calmodulin dependent Protein Kinase II (186-189) should be 
assessed as well.  While they did not appear as top candidates on our human epileptic 
microarrays, they may play roles at different stages of the disease, such as the ability of 
PKC to convert isolated spikes to spike clusters in vitro (169). The drawback of all 
these inhibitors, however, would be that they are not targeted specifically to the abnormal 
areas of brain, but would act generally.  As with many medications, the doses could likely 
be titrated to find an effective level that causes minimal side effects, but the ideal solution 
would be to target drugs directly to the epileptic areas.  The ability to target drugs to 
neurons based on their activity would solve this problem, but that technology may be 
decades away.  Instead, a more immediate solution may be to convert spiking neurons 
from inducing activity-dependent, long-term potentiation (LTP) to inducing activity-
dependent, long-term depression (LTD).  In normal brain, the balance between LTP and 
LTD depends on the discharge timing of the two connected neurons, but application of an 
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alpha1-agonist such as methoxamine can force LTD as the only plasticity option (190-
192).  In the presence of methoxamine, any stimulus would induce LTD in an activity-
dependent manner.  It may therefore be possible to use the hyperactive firing of the 
epileptic focus to preferentially induce LTD in that neuronal network, with less of an 
effect on normal neurons. 
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APPENDIX A 
TABLES 
 
Table 1 – Reviewer agreement on detecting 
individual spikes 
 Percent of spikes marked by: 
 >=2 Reviewers All 3 Reviewers 
Patient 1 12.7 0.0 
Patient 2 30.9 4.3 
Patient 3 26.5 4.9 
Patient 4 17.8 0.5 
Patient 5 39.2 0.7 
Patient 6 18.1 1.3 
Patient 7 35.7 5.9 
Patient 8 16.0 2.9 
Patient 9 32.3 7.4 
Patient 10 8.1 - 
Mean 23.7% 3.1% 
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Table 2 – Spike detection reviewer variability and algorithm performance 
A. HUMAN REVIEWER AGREEMENT WITH OTHER REVIEWERS 
 Reviewer 1 Reviewer 2 Reviewer 3 
 Sensitivity Precision Sensitivity Precision Sensitivity Precision 
Patient 1 13.1 81.0 0.1 100.0 80.8 13.1 
Patient 2 55.1 39.9 15.3 73.6 26.5 53.9 
Patient 3 70.1 29.6 19.5 93.9 13.7 56.1 
Patient 4 21.2 32.5 4.6 58.7 33.2 26.0 
Patient 5 19.4 49.5 31.9 51.8 48.8 64.2 
Patient 6 17.0 33.1 7.8 56.6 35.4 25.5 
Patient 7 45.7 49.8 14.5 75.8 44.9 53.2 
Patient 8 33.7 19.2 11.5 75.0 12.6 31.2 
Patient 9 34.8 61.1 17.7 61.5 45.7 41.2 
Patient 10 9.7 32.7 - - 32.7 9.7 
Mean 32.0 42.8 13.6 71.9 37.4 37.4 
       
B.  RANKING OF CHANNEL ACTIVITY 
  Mean Spearman Rank Coefficient* 
 
Kendall's 
W  Reviewer 1 Reviewer 2 Reviewer 3 Custom script Commercial 
Patient 1 0.653  0.56 0.284 0.529 0.85 0.799 
Patient 2 0.795  0.705 0.708 0.758 0.493 0.585 
Patient 3 0.811  0.747 0.747 0.68 0.551 0.199 
Patient 4 0.802  0.652 0.687 0.755 0.949 0.801 
Patient 5 0.882  0.796 0.822 0.849 0.901 0.817 
Patient 6 0.767  0.561 0.667 0.706 0.834 0.794 
Patient 7 0.838  0.712 0.744 0.823 0.915 0.725 
Patient 8 0.622  0.416 0.448 0.46 0.583 0.352 
Patient 9 0.858  0.821 0.806 0.737 0.697 0.579 
Patient 10 0.49  0.478 - 0.478 0.726 0.09 
Mean 0.752  0.645 0.657 0.678 0.750 0.574 
 
*For human reviewers, this is the average Spearman’s Rho from comparison to the other two 
reviewers.  For the computer scripts, it is Spearman’s Rho when compared to the average channel rank 
determined by the  three human reviewers 
        
C.  CUSTOM SCRIPT’S ABILITY TO IDENTIFY SPIKES MARKED BY: 
 At least 1 Reviewer At least 2 Reviewers All 3 Reviewers 
 Sensitivity Precision Sensitivity Precision Sensitivity Precision 
Patient 1 47.1 58.6 83.1 13.2 100.0 0.1 
Patient 2 42.4 80.6 65.1 38.3 79.0 6.4 
Patient 3 8.3 48.2 24.7 38.0 46.2 13.1 
Patient 4 49.0 60.1 85.8 18.7 87.0 0.6 
Patient 5 33.8 98.9 51.1 58.5 36.0 0.7 
Patient 6 20.8 73.4 51.9 33.0 40.5 1.8 
Patient 7 44.5 86.8 74.5 51.9 78.0 9.0 
Patient 8 30.3 46.0 71.8 17.4 85.7 3.7 
Patient 9 67.8 30.5 82.7 12.0 83.6 2.8 
Patient 10 58.2 19.3 90.7 2.4 - - 
Mean 40.2 60.2 68.1 28.3 70.7 4.3 
       
D.  EXISTING COMMERCIAL SCRIPT’S ABILITY TO IDENTIFY SPIKES MARKED BY: 
 At least 1 Reviewer At least 2 Reviewers All 3 Reviewers 
 Sensitivity Precision Sensitivity Precision Sensitivity Precision 
Patient 1 20.8 52.1 55.7 17.8 100.0 0.1 
Patient 2 45.6 45.3 55.7 17.1 39.5 1.7 
Patient 3 0.0 0.0 0.0 0.0 0.0 0.0 
Patient 4 35.3 92.3 65.1 30.3 46.3 0.7 
Patient 5 29.6 95.9 37.3 47.3 18.7 0.4 
Patient 6 29.8 82.3 59.7 29.7 48.6 1.7 
Patient 7 48.6 100.0 60.0 44.1 16.6 2.0 
Patient 8 23.8 14.4 28.2 2.7 14.3 0.2 
Patient 9 28.3 26.0 27.8 8.3 6.8 0.5 
Patient 10 0.1 100.0 0.8 50.0 - - 
Mean 26.2 60.8 39.0 24.7 32.3 0.8 
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Table 3 - Spikes marked only by script, but later verified by 
reviewers (Out of 10 per patient)  
 Reviewer 1 Reviewer 2 Reviewer 3 
Patient 1 7 0 1 
Patient 2 9 1 4 
Patient 3 10 4 7 
Patient 4 6 1 0 
Patient 5 8 0 5 
Patient 6 6 0 0 
Patient 7 6 0 2 
Patient 8 4 0 0 
Patient 9 0 0 0 
Patient 10 9 0 4 
Mean 6.5 0.6 2.3 
67 
 
 
Table 4 – Lesional patient data 
Patient Tumor type Age Sex 
1 Oligodendroglioma with astrocytic component  - Grade 2 54 M 
2 Oligoastrocytoma – Grade 3 40 M 
3 Oligodendroglioma infiltrating  35 M 
4 Galnglioglioma 22 M 
5 DNET  47 F 
6 Mixed high-grade tumor: Oligoastrocytoma with a nodule of sarcoma – Grade 3 42 F 
7 Anaplastic mixed glioma - Grade 3 36 F 
8  Oligoastrtocytoma - Grades 2 and 3 mixed 44 M 
9 Dermoid cyst 38 F 
10 Epidermoid 50 M 
11 Meningioma (transitional type) 40 F 
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Table 5 – Correlations with interictal spike parameters 
  Non-lesional   Lesional  
  Seizure Category  Seizure Category Distance from tumor 
Frequency 0.111  0.126 0.254 
Amplitude 1 0.133  - -0.134 
Duration 1 -  - 0.144 
Slope 1 0.124  - -0.217 
Amplitude 2 0.121  - -0.213 
Duration 2 -  0.220 - 
Slope 2 -  - -0.205 
Power 0.116  0.144 0.245 
Tumor 
distance -  -0.183 - 
All p<0.01 after correction for multiple comparisons 
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Table 6 – Interictal spike parameters identify seizure onset zone 
 Non-lesional patients 
 
Significant 
Kruskal-Wallis 
Number of patients 
with max value at 
onset electrode 
Number of patients 
with min value at 
onset electrode 
Frequency Yes 4 0 
Amplitude 1 Yes 4 2 
Duration 1 No 1 0 
Slope 1 Yes 4 0 
Amplitude 2 No 4 2 
Duration 2 No 2 2 
Slope 2 No 5 2 
Power Yes 4 0 
    
 Lesional patients 
 
Significant 
Kruskal-Wallis 
Number of patients 
with max value at 
onset electrode 
Number of patients 
with min value at 
onset electrode 
Frequency Yes 2 0 
Amplitude 1 No 4 2 
Duration 1 No 0 2 
Slope 1 No 5 0 
Amplitude 2 No 3 0 
Duration 2 Yes 4 0 
Slope 2 No 5 3 
Power Yes 3 0 
Tumor Distance Yes 2 1 
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APPENDIX B 
FIGURES 
Figure 1 - Spike detection using filtering and block scaling balances 
differences in human reviewers 
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Figure 2 – Frequency and slope of the first halfwave correlate best with 
seizure category in non-lesional patients 
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Figure 3 – Seizure category often lies outside the tumor area, but is 
identified by higher frequency and duration of interictal spiking 
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Figure 4 – Setup of animal model of neocortical interictal spiking 
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Figure 5 – Interictal spiking focus progresses over time 
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Figure 6 – Spikes progressively cluster together with time 
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Figure 7 – Expansion of spike field over time 
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Figure 8 – Interictal spiking causes activity-dependent gene expression 
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Figure 9 – MAPK-CREB inhibition can block the development of an 
interictal spiking focus 
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Figure 10 – Interictal spikes alter rat motility behavior 
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Figure 11 – Interictal spikes can be induced by environmental stimuli 
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Figure 12 – Suppression of interictal spiking with a MEK inhibitor 
normalizes behavior 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
82 
 
Figure 13 – Proposed role of MAPK pathway signaling in this animal model  
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APPENDIX C 
FIGURE LEGENDS 
Figure 1. Spike detection using filtering and block scaling balances differences in 
human reviewers.  (A) Flowchart overview of the detection algorithm.  (B) The 
algorithm’s main initial screening step involves bandpass filtering the data from 20-50Hz 
(bottom), which makes interictal spikes (blue arrows) stand out from background 
compared to more standard viewing filters (top).  This method accentuates both large, 
obvious spikes (left) as well as those that may have otherwise been lost in larger slow 
wave background activity (right).  (C) Scaling all channels together as a block preserves 
differences in spike detection (blue triangles) between more and less active channels.  
Typical methods of scaling each individual channel leads to undermarking of active 
channels and overmarking of less active channels (red squares). (D) Heatmaps of 
interictal spike frequency superimposed on a patient’s 3-dimensional brain rendering 
show that the three human reviewers rank channels similarly, but not identically (top).  
The spike detection algorithm, however, balances reviewer discrepancies and produces a 
similar pattern to the average of all three human reviewers (bottom).   
 
Figure 2 – Frequency and slope of the first halfwave correlate best with seizure 
category in non-lesional patients.  Cortical areas of seizure onset (red) and seizure 
spread (yellow) can best be distinguished from normal areas of brain (green) in non-
lesional patients by higher interictal spike frequency and slope of the first halfwave, as 
demonstrated in this example patient.  Other parameters, such as duration of the first 
halfwave, are not as reliably associated with seizure-generating areas.  (Colored scale bar 
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shows that for each parameters, high values are colored red, intermediate values are 
yellow and low values are green.) 
 
Figure 3 – Seizure category often lies outside the tumor area, but is identified by 
higher frequency and duration of interictal spiking.  In most lesional patients 
(n=7/11), areas of seizure onset (red) lie outside of the immediate tumor area and may not 
be resected as part of a normal tumor resection, as shown in this example patient.  The 
tumor is highlighted as a large, red mass within the temporal lobe.  In contrast to non-
lesional patients, interictal spike frequency is not the best marker for tumor area.  Instead, 
duration of the second halfwave is much more reliable.  Spike frequency is inversely 
correlated with distance from tumor, suggesting that low spike frequencies may aide in 
identifying tumor margins.  (Colored scale bar shows that for each parameters, high 
values are colored red, intermediate values are yellow and low values are green.) 
 
Figure 4 – Setup of animal model of neocortical interictal spiking.  Three electrodes 
are placed over each hemisphere, and one over the nasal sinus as a reference (circles).  
Tetanus toxin is injected under the left, middle electrode (red circle) into the 
somatosensory cortex.  Spikes are initially detected at the injection site in the left, middle 
electrode (L2), as shown by a small example segment of EEG recorded at each of the six 
channels. 
 
Figure 5 – Interictal spiking focus progresses over time. (A) A single injection of 
tetanus toxin causes interictal spikes to develop after a delay of three to five days, which 
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then increase in frequency with time (n=11 animals).  Vehicle animals (n=5) show very 
little spiking and do not change with time.  Tetanus-injected animals have higher spike 
frequency than vehicles by the first week (p=0.029, one-tailed t-test, Bonferroni 
correction; 79.1±18.1 and 9.4±2.9 spikes/ hour, ±  sem), which persists at two weeks 
(p=0.020, one-tailed t-test, Bonferroni correction; 101.3±19.5 and 9.5±2.9 spikes/ hour, ±  
sem) and three weeks (p=0.040, one-tailed t-test, Bonferroni correction; 178.33±45.3 and 
8.6±4.2 spikes/hour±sem) (B) Tetanus-injected animals also initially increase in 
amplitude, which then plateaus by 10 days (Best fit model: y=a*xb+c; R2=0.667). (C) 
Spike slope increases with time (R2=0.530; Linear regression slope=0.307μV/day, 
p=0.0004), while duration does not change much (R2=0.148; Linear regression slope=-
0.299ms/day, p=0.104). (D).  Error bars are standard error of the mean. 
 
Figure 6 – Spikes progressively cluster together with time.  Example EEG samples 
from the same rat show that spikes initially appear as single, isolated discharges in the 
first week.  By the second week, ‘doublets’ become increasingly common, and by three 
weeks longer runs of three to six spikes occur.  Quantifying this increase by calculating 
the percent of spikes in a recording that occur clustered with other spikes shows a 
progressive increase in clustering with time. (n=11; R2=0.492; Linear regression 
slope=0.75%/day, p=0.0025)  
 
Figure 7 – Expansion of spike field over time.  (A) Sample EEG traces from a rat 
which develops spikes predominantly in the left middle (L2) and anterior (L1) channels.  
(B) Heatmap plots of the average amplitudes of spikes in each recording channel over 
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time show the progression in both amplitude and distribution over time.  Similarly, 
example EEG traces (C) and heatmaps (D) show one of the rats which developed right-
sided spikes, despite injection of tetanus toxin on the left.  Averaging the field 
distribution of 11 rats over time (E) shows that spikes begin initially at the injection site, 
but soon spread anteriorly and sometimes contralaterally over time.  No rats showed 
spread to posterior channels. 
 
Figure 8 – Interictal spiking causes activity-dependent gene expression.  Coronal 
brain sections near the injection site show changing patterns of activity-dependent gene 
expression with time via 35S in situ hybridization.  An animal sacrificed after one week 
shows an interesting pattern of increased expression at the injection site, with an annulus 
of suppression surrounding it.  While Egr1 shows this most robustly, the same pattern can 
be seen in superficial layer II with both Narp and Bdnf.  Gapdh shows even expression as 
a non-activity-dependent control.  By two weeks, animals that were sacrificed while the 
spiking focus was still increasing in frequency and amplitude show increased gene 
expression in layers II/III of the spiking hemisphere relative to the contralateral 
hemisphere, while Gapdh expression is even.  By three weeks, the spiking focus of most 
rats has generally stabilized and no longer shows lateralized expression differences, 
despite having focal, left-hemispheric spiking.  Surgery-naïve animals showed even 
expression and antisense probes showed no detectable signal. 
 
Figure 9 – MAPK-CREB inhibition can block the development of an interictal 
spiking focus. (A) By one week after injection of tetanus toxin, most spiking animals 
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(n=5/7) show Creb phosphorylation in layer II/III of the spiking hemisphere relative to 
the contralateral hemisphere.  To attempt to block this activation, the pharmacokinetics of 
a selective MAPK inhibitor were first determined by measuring drug concentrations in 
plasma (B, top) and brain (B, bottom) at multiple time points after intraperitoneal 
injection.  The results of this study were used to determine a dosing regimen of the 
inhibitor which, when given to rats in the week following tetanus toxin injection, reduces 
Creb phosphorylation by immunohistochemistry relative to animals treated with the 
vehicle, DMSO (C).  Rats treated with intraperitoneal injections of 25 mg/kg SL327 
dissolved at 25 mg/kg in DMSO twice daily for one week after tetanus toxin injection 
and then monitored for interictal spiking for four weeks showed significantly decreased 
spike frequency at one week (p=0.005, one-tailed t-test, Bonferroni correction; 79.1 ± 
18.2 and 7.0 ± 3.6 spikes/ hour, ±  sem), 2 weeks (p=0.044, one-tailed t-test, Bonferroni 
correction; 100.5 ± 27.3 and 18.0 ± 9.0 spikes/ hour, ±  sem) and 3 weeks (p=0.013, one-
tailed t-test, Bonferroni correction; 178.3 ± 45.3 and 30.7 ± 7.6 spikes/ hour, ±  sem), 
suggesting that MAPK is necessary for the development of interictal discharges (D).  
Scale bars = 10μm(A,C). 
 
Figure 10 – Interictal spikes alter rat motility behavior  (A)  Monitoring open field 
activity immediately after recording EEG shows that tetanus treated spiking rats are 
consistently hyperactive relative to sham-operated controls (n=4 tetanus, 4 sham; 1 week 
p=0.082, 2 weeks p=0.079, 3 weeks p=0.0005, Bonferroni correction).  (B)  Left versus 
right spike frequency ratio correlates with the ratio of counter-clockwise to clockwise 
rotations rats make (R=0.396, p=0.013).  Similarly, total spike power correlated 
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positively with ambulatory distance (R=0.350, p=0.039 Bonferroni correction) and 
negatively with resting time (R=-0.410, p=0.008 Bonferroni correction). Values within 
each rat were normalized to Z-scores before being compiled for the final correlation. 
 
Figure 11 – Interictal spikes can be induced by environmental stimuli. (A) Study 
overview: Each day of EEG recording, an audio file of a clap is played repeatedly.  The 
first three sounds are spaced 10 minutes apart and are then followed by a train of three 
spaced one second apart.  (B) A rat with spontaneous left-sided spiking has induced 
spikes that appear in the same pattern on the left.  EEG traces show individual examples, 
while the three-dimensional heatmaps show the average of all spontaneous or induced 
spikes for a particular day.  (C) A rat with spontaneous right-sided spiking has induced 
spikes on the right.  All rats showed induced spikes in the same field distribution as the 
rat’s spontaneous spikes.  (D)  The amplitude of induced spikes increased over time as 
each rat’s spontaneous spikes increased in amplitude.  The scatter plot shows the 
amplitude of induced spikes versus the amplitude of spontaneous spikes, normalizing the 
values within each rat so that the highest value is 100%.  (R=0.535, p=1.42x10-9).  (E)  
When a train of sounds only one second apart is played, EEG response to the stimulus 
extinguishes rapidly, likely because rats no longer appear startled by the sound. 
 
Figure 12 – Suppression of interictal spiking with a MEK inhibitor normalizes 
behavior.  Monitoring open field activity while simultaneously recording EEG shows 
that tetanus treated rats increase in ambulation over time as spiking increases, but 
treatment with a selective inhibitor of a component of the MAPK pathway, SL327, 
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during the first week after tetanus injection prevents this increase.  Rats were 
administered intraperitoneal injections of 25 mg/kg SL327 dissolved at 25 mg/kg in 
DMSO twice daily for one week following surgery.  By two weeks, rats given tetanus 
alone ambulate significantly more than rats given tetanus and SL327 (p=0.025) and this 
difference widens by week 3 (p=0.012).  SL327 animals were similar to animals injected 
with a vehicle solution (0.01M sodium phosphate) instead of tetanus toxin 
(729.4±93.2cm; not shown).   
 
Figure 13 – Proposed role of MAPK pathway signaling in this animal model.  The 
MAPK pathway can be activated both by calcium influx into the cell and by binding of 
BDNF to its receptor, TrkB.  Intracellular calcium can be increased by the binding of 
glutamate to ionotropic glutamate receptors (AMPA and NMDA types) or by activation 
of voltage-gated calcium channels (VGCC) (193).  The resulting increase in intracellular 
calcium (Ca2+) binds to and activates calmodulin, which in turn binds to Ras protein-
specific guanine nucleotide-releasing factor 1 (Ras-GRF1) (194,195).  Ras-GRF1 acts as 
a guanine nucleotide exchange factor (GEF) which causes Ras to release guanosine 
diphosphate (GDP) and instead bind guanosine triphosphate (GTP), thus activating Ras.  
From the TrkB receptor side, binding of BDNF to a TrkB homodimer causes 
autophosphorylation of tyrosine residues in the intracellular kinase domain of the 
receptor (196). Phosphorylation of a tyrosine at position 515 in the juxtamembrane region 
of TrkB recruits Shc adaptor molecules through their phosphotyrosine-binding (PTB) 
domains (197).  The recruitment and phosphorylation of Shc adaptors leads to the binding 
of growth factor receptor-bound protein 2 (GRB2) complexed with son of sevenless 
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(SOS) (198) , which acts as a GEF to activate Ras to the GTP-bound form (199).  Active 
Ras then phosphorylates mitogen-activated protein kinase (MEK), which in turn 
phosphorylates extracellular signal-regulated kinases 1 and 2 (200).  ERK can both 
translocate to the nucleus and phosphorylate cytosolic ribosomal S6 kinase (p90-RSK) 
which itself translocates to the nucleus (201-203).  Once inside the nucleus, p90-RSK 
phosphorylates the transcription factor, cyclic AMP response element binding protein 
(CREB)(202).  Nuclear ERK can also lead to CREB phosphorylation through mitogen- 
and stress-activated protein kinase (MSK)(202).  ERK phosphorylates a variety of 
additional targets, including ets-like gene1 (Elk1) shown here (133).  Genes whose 
transcripts were found upregulated in this project include early growth response 1 
(EGR1), neuronal activity-regulated pentraxin (NARP) and brain-derived neurotrophic 
factor (BDNF).  EGR1 is an immediate early gene (IEG) rapidly induced after long-term 
potentiation(LTP)-inducing stimuli (204).  EGR1 is a direct target for pCREB, since the 
EGR1 promoter contains binding sites for both Elk-1 and CREB, and both these proteins 
were found to be phosphorylated coincident with the onset of EGR1 expression after 
glutaminergic stimulation in vivo (150-152).  Additionally, inhibition of the MAPK 
pathway prevents phosphorylation of both these proteins, prevented EGR1 induction and 
resulted in rapidly decaying LTP (133).  EGR1 causes transcription of a variety of other 
mRNAs, many of which are involved in synaptic plasticity (138).  The control of NARP 
transcription has not been well studied, but the NARP promoter contains a CREB binding 
site, and NARP is an IEG upregulated in neurons by physiologic synaptic activity and by 
BDNF-induced LTP (154,155).  It is a pentameric protein secreted at synapses where it 
clusters AMPA receptors together and mediates synaptic refinement (205-207).  BDNF 
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has been shown to have a functional CRE (153) and has long been known to play a role 
in synaptic plasticity and LTP (137,208-211).  BDNF is secreted in an activity-dependent 
manner from both pre- and post-synaptic terminals and can bind to TrkB receptors on 
both surfaces, leading to further MAPK pathway activation and causing modulation of 
neurotransmitter signaling (212-216). 
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Epilepsy is one of the most common neurological diseases, affecting up to 1% of 
the world population.  Epilepsy remains poorly understood and there are currently no 
medications to cure it.  Patients with epilepsy have both seizures as well as another type 
of abnormal activity between seizures, known as interictal spikes.  Interictal spikes have 
thus far been poorly researched, yet growing evidence supports an important role for 
them in epilepsy.  In this project, we first show the high variability between reviewers in 
marking interictal spikes on intracranial EEG, and then develop and test an automated 
detection method to solve this problem.  Next, we use this automated detection algorithm 
to identify spikes on intracranial EEG in both tumor and non-tumor patients in order to 
determine the best spiking parameters to identify the seizure onset zone in each group.  
We then develop and characterize an animal model of chronic, neocortical interictal 
spiking to test our observations previously made in human epilepsy and to have a 
molecularly-accurate model on which to test new therapeutics.  Finally, we show that 
interictal spikes are associated with behavioral changes in this animal model and that a 
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targeted inhibitor can both prevent the development of a spiking focus and normalize 
behavior. 
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